
ã³ãããäžçäžã§çåšãæ¯ãã£ãŠããé ãæ¯æ¥ã®ããã«ãã¬ãã§ææè æ°ãå ±ããããã¯ã¯ãã³æ¥çš®ã倧ããåŒã³ãããããŠããŸãããç§èªèº«ã«ãšã£ãŠããè·åæ¥çš®ãå€§èŠæš¡æ¥çš®äŒå Žãªã©ã瀟äŒå šäœãã¯ã¯ãã³æ¥çš®ã«åãã£ãŠåããŠããããšã¯ããŸã ããã»ã©æã®ããšã«ã¯æããŸããã
ããããçŽ5幎ãæè¿ã§ã¯ãåœæã®ããã«ç€ŸäŒå šäœã§ãã³ããã¯ã¯ãã³ãæã¡ãŸãããããšããåŒã³ãããç®ã«ããããšã¯ãããªãå°ãªããªããŸããã
ãã¡ãããã³ããã¯ã¯ãã³ãã®ãã®ããªããªã£ãããã§ã¯ãããŸãããçŸåšã®æ¥æ¬ã§ã¯ã65æ³ä»¥äžãªã©éçåãªã¹ã¯ã®é«ã人ãäžå¿ãšãã宿æ¥çš®ã«å€ãã£ãŠããã2024幎床以éã¯æ¥çš®ã®åªå矩åãèªæ²»äœã«ããæ¥çš®å§å¥šããªããªã£ãŠããŸããåçåŽåç
ãããªç¶æ³ãèŠãŠããŠããµãšçåã«æããŸããã
ããã ãå€ãã®äººãæ¥çš®ããã³ããã¯ã¯ãã³ã¯ãçµå±ã®ãšããæ¬åœã«å¿ èŠã ã£ãã®ã§ããããã
ããããSNSãèŠãã°ããå€ãã®åœãæã£ãããšãã話ãããäžæ¹ã§ããå¯äœçšã§å€ãã®äººã亡ããªã£ãããè¶ éæ»äº¡ãå¢ãããã補è¬äŒç€Ÿãè«å€§ãªå©çãåŸãããã ã£ãããmRNAã¯ã¯ãã³ã¯éºäŒåã«åœ±é¿ããããšãã£ã話ãåºãŠããŸãã
ããã«ãåœæãã¬ãã§é »ç¹ã«èŠãããå°éå®¶ãæ¿åºã®èª¬æã«ã€ããŠããæ¬åœã«æ£ããã£ãã®ããã補è¬äŒç€Ÿãšã®é¢ä¿ã¯ãªãã£ãã®ãããšçåãæã€äººãããããã§ãã
ç§ã¯å»åž«ã§ãç ç©¶è ã§ããããŸããããããŠããã®èšäºã§ãã¯ã¯ãã³ã¯æ£ããã£ããããããééã£ãŠããããšãæåããã©ã¡ããã®çµè«ã蚌æãããããã§ããããŸããã
ãã ãããã ããããããªè©±ãåºãŠããã®ã«ã¯ãäœãçç±ãããã¯ãã§ãã
ããã§ä»åã¯ãåçåŽåçãPMDAãWHOãªã©ã®å ¬çè³æãç ç©¶è«æã補è¬äŒç€Ÿã®æ±ºç®è³æãåœäŒè°äºé²ãªã©ãã§ããéã確èªããªããããå®éã«ç¢ºèªãããããšããäžéšã¯äºå®ã ã£ãããšãããŸã åãã£ãŠããªãããšããçŸåšã®èšŒæ ã§ã¯æ¯æãããŠããªãããšããåããŠèª¿ã¹ãŠã¿ãŸãããä»åã®èª¿æ»èªäœãã2020ïœ2022å¹Žåœæã«åãã£ãŠããããšãšã2026幎ãŸã§ã«åŸããåãã£ãããšãåºå¥ããŠæ€èšŒããŠããŸãã
調ã¹ãåã®ç§ã¯ãæçµçã«ã¯ãå¿ èŠã ã£ããããå¿ èŠãªãã£ããããã©ã¡ããã®çãã«ãã©ãçãã®ã§ã¯ãªãããšæã£ãŠããŸããã
ã§ããå®éã«èª¿ã¹ãŠã¿ããšã話ã¯ãããªã«åçŽã§ã¯ãããŸããã§ããã
ãã®èšäºã§ã¯ããã®é ãããäžåºŠæ¯ãè¿ããªãããã³ããã¯ã¯ãã³ã«ã€ããŠä»ã ããåããããšããäžã€ãã€æŽçããŠãããããšæããŸãã
â»ãã®èšäºã¯2026幎9ææç¹ã§ç¢ºèªã§ããå ¬çè³æã»ç ç©¶ãããšã«ãŸãšããŠããŸããå¶åºŠãå»åŠçç¥èŠã¯ä»åŸæŽæ°ãããå¯èœæ§ããããŸãã
- å ã«çµè«ããå¿ èŠã ã£ãïŒå¿ èŠãªãã£ããã§ã¯å²ãåããªãã£ã
- ãŸãã2021å¹Žåœæã®ç¶æ³ãå¿ããŠã¯ãããªã
- å®éãã³ããã¯ã¯ãã³ã«ã¯ã©ããããã®å¹æããã£ãã®ã
- å¯äœçšããæ¥çš®åŸã«äº¡ããªã£ãããšãã話ã¯ãæ¬åœã ã£ãã®ã
- ã§ã¯ãã¯ã¯ãã³æ¥çš®åŸã«äº¡ããªã£ã人ã倿°ããããšãã話ã¯ïŒ
- ãmRNAã¯ã¯ãã³ã¯éºäŒåãæžãæããããšããè©±ã¯æ¬åœãªã®ã
- mRNAãšDNAã¯ãããããåããã®ã§ã¯ãªã
- ã§ã¯ããäœå ã§ããã«å šéšæ¶ããããšãã説æã¯æ£ããã£ãã®ã
- ãã¯ã¯ãã³ã«DNAãå ¥ã£ãŠããããšãã話ããã£ã
- ãäžåŠã«ãªãããšãã話ã¯ã©ãã ã£ãã®ã
- ãã¿ãŒãçããã¯ã¯ãã³ã§ãããå¢ããããšãã話ã¯ïŒ
- 調ã¹ãŠã¿ããšããå®å šãªããããšäžèšã§çã¥ããã®ãéãæ°ããã
- ãã¯ã¯ãã³æ¥çš®ãå§ãŸã£ãŠããè¶ éæ»äº¡ãå¢ããããšããè©±ã¯æ¬åœãªã®ã
- 補è¬äŒç€Ÿãã¯ã¯ãã³ã§è«å€§ã«å²ãããšããã®ã¯ãæ¬åœã ã£ãã®ã
- Pfizerã®ã¯ã¯ãã³å£²äžã¯ã幎éçŽ380åãã«
- BioNTechãšModernaã¯ãå®éã«å·šé¡ã®å©çãäžããŠãã
- éçºã«ã¯å ¬çãªãéã䜿ãããŠãã
- ããããæ¿åºãšã®å¥çŽå 容ã«ã¯éå ¬ééšåããã£ã
- æ¥æ¬ã§ãã¯ã¯ãã³ã®è³Œå ¥å䟡ã¯å ¬è¡šãããªãã£ã
- ãããŸã§ç¥ããšããäœãããã®ã§ã¯ïŒããšæãæ°æã¡ã¯åãã
- ã補è¬äŒç€Ÿãå²ãã£ãããšãã¯ã¯ãã³ãäžèŠã ã£ããã¯å¥ã®è©±
- ãããŸã§èª¿ã¹ãŠãããèãè©±ãæŽçããŠã¿ã
- ãªãä»ã¯ããã®é ã»ã©ã¯ã¯ãã³ãæã€ããã«èšãããªããªã£ãã®ã
- 2021幎ãšä»ã§ã¯ãããããã®æ¡ä»¶ãããªãéã
- ãŠã€ã«ã¹èªäœãå€ãã£ã
- æ¥æ¬ã®å¶åºŠããå®éã«å€§ããå€ãã£ãŠãã
- é«éœ¢è ãšè¥ã人ãåãããã«èããªããªã£ãããšã倧ãã
- æ²»çæ³ãå¢ããããšãç¡èŠã§ããªã
- ã ããããæã¯æ£ããã£ãïŒä»ã¯ééãããšãã話ã§ããªã
- çµå±ãã³ããã¯ã¯ãã³ã¯æ¬åœã«å¿
èŠã ã£ãã®ã
- 2021幎ã®é«éœ¢è ãžã®æ¥çš®ãšããã®åŸã®è¥ã人ãžã®è¿œå æ¥çš®ã¯åã話ã§ã¯ãªã
- ã¯ã¯ãã³ã«å¹æããã£ãããšãšãåé¡ããªãã£ãããšãå¥ã ã£ã
- ã ãããšãã£ãŠããå šéšãŠãœã ã£ããã«ããªããªãã£ã
- ãé°è¬è«ããšç¬ã£ãŠçµããããã®ãéããšæã£ã
- 5幎çµã£ãä»ã ãããå°ãå·éã«èŠãããããšããã
- 調ã¹ãåãããçãã¯å°ãè€éã«ãªã£ã
- æåŸã«
å ã«çµè«ããå¿ èŠã ã£ãïŒå¿ èŠãªãã£ããã§ã¯å²ãåããªãã£ã
ããªãã®è³æãèªãã§ã¿ãŠãæåã«æããã®ã¯ããã³ããã¯ã¯ãã³ã¯å¿ èŠã ã£ãã®ãïŒããšããåãèªäœããæã£ãŠãã以äžã«çããã®ãé£ãããšããããšã§ããã
ãšããã®ããã誰ã«ãšã£ãŠå¿ èŠã ã£ãã®ããããã€ã®æç¹ã®è©±ãªã®ããã§ãçããããªãå€ããããã§ãã
2020幎æ«ãã2021幎ã«ãããŠã¯ããŸã æ°åã³ããã«å¯Ÿããå ç«ãæã£ãŠããªã人ãå€ããç¹ã«é«éœ¢è ãåºç€çŸæ£ã®ãã人ã§ã¯ãææããå Žåã®éçåãæ»äº¡ã®ãªã¹ã¯ãé«ãç¶æ³ã§ãããåœæã®èšåºè©Šéšãããã®åŸã®å®ç€ŸäŒã®ããŒã¿ãèŠãéãããããã人ãã¡ãžã®ååæ¥çš®ã«ã¯ãããªãåŒ·ãæ ¹æ ããã£ããšèããããŸãã
äžæ¹ã§ã20代ã®å¥åº·ãªäººãåã©ããŸã§åãããã«èããŠããã®ããšãããšãããåçŽã§ã¯ãããŸããã
ããšããšã®éçåãªã¹ã¯ãäœããã°ãã¯ã¯ãã³ã«ãã£ãŠåŸããã絶察çãªå©çãå°ãããªããŸããããã«2021幎ã«ã¯ãç¹ã«è¥ãç·æ§ã§mRNAã¯ã¯ãã³æ¥çš®åŸã®å¿ççã»å¿èçãå¢ããããšãåãã£ãŠããŸããã
ãŸãããã¯ã¯ãã³ãæãŠã°ã³ããã«ææããªãããšãããã®ã§ããããŸããã§ããã
åæã«ã¯ææãçºçãä»äººãžã®äŒæãæžãã广ã確èªãããŠããŸãããããã®å¹æã¯æéãšãšãã«äœäžããDeltaããããŠOmicronãžãšãŠã€ã«ã¹ãå€åããã«ã€ããŠãææãã®ãã®ãé²ãåã¯åŒ±ããªã£ãŠãããŸãããäžæ¹ã§ãå ¥é¢ãéçåãé²ã广ã¯ãç¹ã«é«éœ¢è ã§ã¯æ¯èŒçæ®ã£ãŠããããšãåãã£ãŠããŸãã
ã€ãŸãã
ãææãé²ããªãã£ãã®ã ããã¯ã¯ãã³ã«ã¯æå³ããªãã£ãã
ãšããã®ãæ£ç¢ºã§ã¯ãããŸãããã
ãæãŠã°ææããªããã人ã«ããã€ããªãã
ãšãã説æãæ£ç¢ºã§ã¯ãªãã£ãããšããããšã§ãã
ãããŠããããä»å調ã¹ãŠããŠããªãéèŠã ãšæã£ããšãããªã®ã§ããã2021幎ã«åããŠæ¥çš®ãããšãã®è©±ãšãOmicron以éã«3åç®ã4åç®ã5åç®ãšè¿œå æ¥çš®ãã話ããåããã®ãšããŠèããããšã¯ã§ããŸããã
å®éãçŸåšã®æ¥æ¬ã§ã¯2021å¹Žåœæã®ãããªå šäžä»£ã察象ãšããå€§èŠæš¡ãªæ¥çš®ã§ã¯ãªãã65æ³ä»¥äžãªã©éçåãªã¹ã¯ã®é«ã人ãäžå¿ãšãã宿æ¥çš®ãžãšå¶åºŠãå€ãã£ãŠããŸããåçåŽåçããçŸåšã®å®ææ¥çš®ã®ç®çãäž»ã«ãå人ã®éçåäºé²ããšããŠããŸããåçåŽåç
ã ããä»åã®èšäºã§ã¯ã
ãã³ããã¯ã¯ãã³ã¯è¯ãã£ãã®ããæªãã£ãã®ãã
ãšäžæ¬ãã«ã¯ããŸããã
2021幎ã®é«éœ¢è ãžã®ååæ¥çš®ãå¥åº·ãªè¥ã人ãžã®æ¥çš®ãOmicron以éã®è¿œå æ¥çš®ããããããåããªãããå®éã«ã©ã®ãããªå¹æããããã©ã®ãããªãªã¹ã¯ãåãã£ãŠããã®ããèŠãŠãããŸãã
ãã®ããã«ã¯ãŸããã¯ã¯ãã³æ¥çš®ãå§ãŸã£ã2021å¹Žåœæãããã£ããã©ããªç¶æ³ã ã£ãã®ããæãåºãå¿ èŠããããŸãã
ãŸãã2021å¹Žåœæã®ç¶æ³ãå¿ããŠã¯ãããªã
ä»ã«ãªã£ãŠã³ããã¯ã¯ãã³ãæ¯ãè¿ããšããã©ãããŠãçŸåšã®æèŠã§èããŠããŸããŸãã
ã§ãã2021å¹Žåœæãš2026幎ã®ä»ã§ã¯ãåæãããªãéããŸãã
2020幎ãã2021幎ã«ãããŠã¯ããŸã æ°åã³ããã«ææããçµéšã®ãã人ããã¯ã¯ãã³ãæ¥çš®ãã人ãå°ãªãã瀟äŒå šäœãšããŠå ç«ãæã€äººãããªãå°ãªãç¶æ ã§ããã2020幎6æã«è¡ãããæäœèª¿æ»ã§ã¯ãæäœä¿æçã¯æ±äº¬0.10ïŒ ã倧éª0.17ïŒ ãå®®å0.03ïŒ ãšéåžžã«äœãæ°åã§ããã
æ²»çæ³ãä»ã»ã©æŽã£ãŠããŸããã§ããã
ãã®åŸããããµã¡ã¿ãŸã³ãªã©æå¹ãªæ²»çã䜿ãããããã«ãªããããã«æãŠã€ã«ã¹è¬ãªã©ãç»å ŽããŠãããŸãããã¯ã¯ãã³æ¥çš®ãå§ãŸã£ãé ã¯ãææããå Žåã®éçåãã©ãé²ããã«ã€ããŠãä»ããéžæè¢ãå°ãªãã£ãææã§ãã
ãããŠãé«éœ¢ã«ãªãã»ã©ææããå Žåã®æ»äº¡ãªã¹ã¯ãæ¥æ¿ã«äžããããšããæ¯èŒçæ©ã段éããåãã£ãŠããŸããã
æµ·å€ã®æµè¡åæã®ããŒã¿ããŸãšããç ç©¶ã§ã¯ãææããå Žåã®æ»äº¡ãªã¹ã¯ã¯55æ³ã§çŽ0.4ïŒ ã65æ³ã§çŽ1.4ïŒ ã75æ³ã§çŽ4.6ïŒ ã85æ³ã§çŽ15ïŒ ãšæšå®ãããŠããŸãããã¡ãããããã¯2020å¹Žåœæã®æµ·å€ããŒã¿ãçµ±åããæšèšãªã®ã§ããã®ãŸãŸæ¥æ¬äººäžäººã²ãšãã«åœãŠã¯ããããšã¯ã§ããŸããã
ããã§ãããè¥ã人ãšé«éœ¢è ã§ã¯ãªã¹ã¯ããŸã£ããéãããšããããšã¯èŠããŠããŸããã
倧éªã§ã¯éçç åºã®éçšçã99.7ïŒ ã«ãªã£ãææããã£ã
ç§ãäœãã§ãã倧éªã§ãã2021幎æ¥ã¯ããªãå³ããç¶æ³ã§ããã
倧éªåºã®2021幎5æ12æ¥ã®äŒèŠã§ã¯ãå®éã«éçšããŠããéçç åº356åºã«å¯ŸããŠ355人ãå ¥é¢ãã*éçç åºã®éçšçã¯99.7ïŒ ãšèª¬æãããŠããŸããããã«ãéçç åºä»¥å€ã®äžççç é¢ã§ãæ¿ç®¡ãªã©ã®éçæ²»çãåããŠãã人ã46人ããŸããã倧éªåºå ¬åŒãµã€ã
ã€ãŸãããç é¢ããã£ã±ãã ããšããã®ã¯åãªãé°å²æ°ã§ã¯ãªããå®éã«å»çæäŸäœå¶ãããªãå³ãããªã£ãææããããŸããã
ãã ãããã®99.7ïŒ ãšããæ°åãæ³šæãå¿ èŠã§ããããã¯å šåœã®ICU䜿çšçã§ãã倧éªã«ååšãããã¹ãŠã®éçç åºã«å¯Ÿããæ°åã§ããªãããã®æç¹ã§ã³ããæ£è åãã«å®éã«éçšããŠããéçç åºã®äœ¿çšç¶æ³ã§ãã倧éªåºèªèº«ãåœæããéçã»è»œçäžççç åºãšãäŸç¶æ¥µããŠå³ããç¶æ³ããšèª¬æããŠããŸãã倧éªåºå ¬åŒãµã€ã
ããããç¶æ³ã®äžã§ã2021幎ã«ã¯ã¯ãã³æ¥çš®ãæ¬æ Œçã«å§ãŸããŸããã
ãããé£ã°ããŠã
ãä»ã¯æ®éã«ç掻ã§ããŠããã®ã ãããåœæãã¯ã¯ãã³ãªããŠå¿ èŠãªãã£ãã®ã§ã¯ïŒã
ãšèããŠããŸããšãå°ãéã£ãèŠãæ¹ã«ãªã£ãŠããŸããŸãã
ä»ã¯ãã¯ã¯ãã³æ¥çš®ãèªç¶ææã«ãã£ãŠå ç«ãæã€äººãå¢ãããŠã€ã«ã¹èªäœãå€åããæ²»çæ³ãå¢ããŠããŸãã
ã ãããã2026幎ã®ä»ãªãã©ããããããšã2021幎ã®ãã®ç¶æ³ã§ã©ã倿ããããã¯ãåããŠèããå¿ èŠããããŸãã
ç§èªèº«ãä»å調ã¹ããŸã§ã¯ããã®éãããããŸã§æèããŠããŸããã§ããã
ã§ã¯ããã®2021å¹Žåœæãã¯ã¯ãã³ã«ã¯å®éã©ããããã®å¹æããã£ãã®ã§ããããã
次ã¯ãããèããã95ïŒ æå¹ããšããæ°åããããããäœãæå³ããŠããã®ãããèŠãŠãããŸãã
å®éãã³ããã¯ã¯ãã³ã«ã¯ã©ããããã®å¹æããã£ãã®ã
ã³ããã¯ã¯ãã³ã«ã€ããŠèª¿ã¹ãŠãããšããŸãåºãŠããã®ãã95ïŒ ã®æå¹æ§ããšããæ°åã§ãã
ç§ãåœæããã®ã95ïŒ ããšããæ°åãäœåºŠãèŠãèšæ¶ããããŸãããã ãä»åãããããŠèª¿ã¹ãŠã¿ããšããã®æ°åã«ã€ããŠç§ã¯å°ã誀解ããŠããŸããã
ã95ïŒ æå¹ãã¯ã95ïŒ ã®äººãææããªããšããæå³ã§ã¯ãªãã£ã
Pfizer/BioNTechã®åæã®èšåºè©Šéšã§ã¯ã2åç®ã®æ¥çš®ãã7æ¥ä»¥éã«çç¶ã®ããCOVID-19ãçºçãã人ã¯ãã¯ã¯ãã³æ¥çš®çŸ€18,198人ã®ãã¡8人ããã©ã»ã矀18,325人ã®ãã¡162人ã§ããã
ãã®å·®ããç®åºãããã®ããçŽ95ïŒ ãšãããæå¹çãã§ãã
ãã ããããã¯ãã¯ã¯ãã³ãæã£ã人ã®95ïŒ ãã³ããã«ããããªãã£ãããšããæå³ã§ã¯ãããŸããã
ãã®è©Šéšã§ã¯ãçºçããå²åã¯ãã©ã»ã矀ã§çŽ0.88ïŒ ãã¯ã¯ãã³çŸ€ã§çŽ0.04ïŒ ã§ãããã€ãŸãããã®èг坿éã«ããã絶察çãªå·®ã¯çŽ0.84ãã€ã³ãã§ãã
ãã ãããã®0.84ãã€ã³ãã¯ããã®èšåºè©Šéšã®èг坿éäžã«ãçç¶ã®ããCOVID-19ãçºçããå²åãã®å·®ã§ãã95ïŒ ãš0.84ãã€ã³ãã¯åã詊éšçµæãå¥ã®æ¹æ³ã§è¡šããæ°åã§ãã©ã¡ããäžæ¹ã ããæ£ãããšããæå³ã§ã¯ãããŸããã
åã詊éšçµæãªã®ã«ãæ°åããåããå°è±¡ã¯ããã¶ãéããŸãã
ãã¡ãããã ãã95ïŒ ãšãã衚çŸãééãã ã£ãããã§ã¯ãããŸãããå»è¬åã®å¹æãæ¯èŒãããšãã«äœ¿ããããçžå¯Ÿãªã¹ã¯æžå°ããšããææšã§ãèšç®ãšããŠã¯æ£ããæ°åã§ãã
ãã ãç§ã®ãããªäžè¬ã®äººãã95ïŒ æå¹ããšèãããšãã«ãäœã95ïŒ ãªã®ããŸã§æ£ç¢ºã«çè§£ããŠããããšãããšãå°ãæªããæ°ãããŸãã
ããã«ããã®èšåºè©Šéšãè¡ãããã®ã¯2020幎ããŸã Omicronã©ãããDeltaãç»å Žããåã§ãã¯ã¯ãã³ãæ¥çš®ãã人ãèªç¶ææãã人ãå°ãªãã£ãææã§ãã
ãããã£ãŠããã®ã95ïŒ ããããã®åŸã®ãã¹ãŠã®å€ç°æ ªããã¹ãŠã®å¹Žä»£ã3åç®ã4åç®ä»¥éã®æ¥çš®ã«ããã®ãŸãŸåœãŠã¯ããããšã¯ã§ããŸããã
ããã§ããåæã®ã¯ã¯ãã³ã«ã¯ã¯ã£ãããã广ããã£ã
äžæ¹ã§ãã95ïŒ ãšããæ°åã®èŠãæ¹ã«æ³šæãå¿ èŠã ã£ããããšãšããã¯ã¯ãã³ã«å¹æããªãã£ããããšãå¥ã®è©±ã§ãã
åæã®èšåºè©Šéšã ãã§ãªãããã®åŸã®å®ç€ŸäŒã®ããŒã¿ã§ããææãçºçã ãã§ãªããå ¥é¢ãéçåãæžãã广ã確èªãããŸãããç¹ã«é«éœ¢è ãéçåãªã¹ã¯ã®é«ã人ã«ãšã£ãŠã¯ããã®å¹æã倧ããªæå³ãæã£ãŠãããšèããããŸãã
ãããŸã§ã¯ãä»åããªãå€ãã®è³æãèªãã§ãã倧ããèŠããããªè©±ã§ã¯ãããŸããã§ããã
ã§ã¯ãããèãã
ãã§ãçµå±ãã¯ã¯ãã³ãæã£ãŠãã³ããã«ææãããããªããã
ãšããçåã¯ã©ããªã®ã§ããããã
ã¯ã¯ãã³ãæã£ãŠãææãããããã¯éäžããåãã£ãããšãªã®ãïŒ
ããã«ã€ããŠãã話ã¯å°ãè€éã§ãã
åæã«ã¯ãã¯ã¯ãã³ã«ãã£ãŠææãã®ãã®ãæžããä»äººãžã®ææãããçšåºŠæžãã广ã芳å¯ãããŠããŸãããDeltaæµè¡æã®è±åœã®ç ç©¶ã§ããæ¥çš®ãã人ããåšå²ãžã®ææãæžå°ããåŸåã確èªãããŠããŸãã
ãšãããããã®å¹æã¯ãã£ãšåãã§ã¯ãããŸããã§ããã
æ¥çš®ããæéãçµã€ã«ã€ããŠææäºé²å¹æãäœäžããããã«Omicronã®ããã«å ç«ãããæããããå€ç°æ ªãåºãããšããææãã®ãã®ãé²ãããšããã¯ã¯ãã³ã®åœ¹å²ã¯ããªãå°ãããªã£ãŠãããŸããã
äžæ¹ã§ãå ¥é¢ãéçåãé²ã广ã¯ãææäºé²å¹æã»ã©æ¥æ¿ã«ã¯å€±ãããŸããã§ãããç¹ã«é«éœ¢è ã§ã¯ããã®åŸã®æŽæ°ã¯ã¯ãã³ã§ãå ¥é¢ãæžãã广ã確èªãããŠããŸãã
ã€ãŸãã
ãææãã人ãããããã¯ã¯ãã³ã¯å¹ããªãã£ãã
ãšã¯èšããŸããã
ãã ãå察ã«ã
ãã¯ã¯ãã³ãæãŠã°ææããªããã ããä»äººã«ãææãããªãã
ãšãŸã§èšã£ãŠããŸãã®ããå°ãªããšããã®åŸã«åãã£ãŠããäºå®ãšã¯åããŸããã
ãã®éãããä»åã¯ã¯ãã³ã«ã€ããŠãããããªçåãäžä¿¡æãçãŸããçç±ã®äžã€ãªã®ã§ã¯ãªããããšç§ã¯æããŸããã
ãããŠãããããããäžã€éèŠãªçåãåºãŠããŸãã
广ããã£ããšããŠããããã«ãã£ãŠèµ·ããå¯äœçšãå¥åº·è¢«å®³ã¯ãã©ã®çšåºŠãã£ãã®ã§ããããã
次ã¯ãã¯ã¯ãã³ãããã話ã®äžã§ãç¹ã«æ°ã«ãªããå¿ççãå¯äœçšããããŠãæ¥çš®åŸã«äº¡ããªã£ãããšãã話ã調ã¹ãŠãããŸãã
å¯äœçšããæ¥çš®åŸã«äº¡ããªã£ãããšãã話ã¯ãæ¬åœã ã£ãã®ã
ã¯ã¯ãã³ã«ã€ããŠèª¿ã¹å§ãããšãé¿ããŠéããªãã®ãå¯äœçšã®è©±ã§ãã
ãããã§ã¯ãå¯äœçšãªããŠã»ãšãã©ãªãã£ãããšããæèŠãããã°ããã¯ã¯ãã³ã®ããã§å€ãã®äººã亡ããªã£ãããšãã話ãèŠãããŸãã
ã§ã¯ãå®éã®ãšããã¯ã©ãã ã£ãã®ã§ããããã
調ã¹ãŠã¿ããšãããã§ãã©ã¡ããäžæ¹ã ããèŠãŠãããšã宿 ããé¢ããŠããŸãããšãåãããŸããã
å¿ççãªã©ãå®éã«ç¢ºèªãããé倧ãªå¯åå¿ã¯ãã
ãŸãããé倧ãªå¯åå¿ã¯ãªãã£ãããšããã®ã¯æ£ç¢ºã§ã¯ãããŸããã
mRNAã¯ã¯ãã³ã®æ¥çš®åŸã«ã¯ããŸãã§ã¯ãããã®ã®ãå¿ççãå¿èçãå¢ããããšã確èªãããŠããŸãã ç¹ã«å€ãã£ãã®ããè¥ãç·æ§ã®2åç®æ¥çš®åŸã§ããã
ã¢ã¡ãªã«ã®2021幎ã®ç£èŠããŒã¿ã§ã¯ã2åç®æ¥çš®åŸã®å¿ççå ±åã¯ã12ïœ17æ³ã®ç·åã§100äžåãããçŽ63ä»¶ã18ïœ24æ³ã®ç·æ§ã§çŽ51ä»¶ã§ããã
æ¥æ¬ã§ãåãåŸåã確èªãããŠããŸãã
åçåŽåçã®è³æã§ã¯ã10ä»£ç·æ§ã«ã€ããŠã1åç®ãš2åç®ãåãããå¿çççãã®å ±åé »åºŠããPfizerã§ã¯100äžäººãããçŽ25ïœ26ä»¶ãModernaã§ã¯çŽ80ïœ98ä»¶ãšãããŠããŸããã
ãã ãããã®æ°åã«ã泚æãå¿ èŠã§ãã
ããã¯èªçºçã«å ±åããããçãäŸããéèšãããã®ã§ããã¹ãŠãã¯ã¯ãã³ã«ãã£ãŠèµ·ãããšèšŒæãããæ°åã§ã¯ãããŸããããŸããã¯ã¯ãã³ã®çš®é¡ãæ¥çš®åæ°ãå¹Žéœ¢ãæ§å¥ã«ãã£ãŠãªã¹ã¯ã¯å€§ããéããŸãã
ããã§ããè¥ãç·æ§ã§å¿ççãå¢ãããšããå®å šæ§äžã®ã·ã°ãã«ãã®ãã®ã¯ããã®åŸã®ç ç©¶ãå«ããŠç¢ºèªãããŠããŸãã
ã€ãŸããããã¯åãªããããäžã®åã§ã¯ãããŸããã
ãã»ãšãã©ã®äººãå埩ãããã§çµããããŠããã®ã
æ¥çš®åŸã«èµ·ããå¿ççã«ã€ããŠã¯ãå€ãã®äººãéé¢ããçç¶ãæ¹åããããšãå ±åãããŠããŸãã
äžæ¹ã§ããã®åŸã®æ€æ»ã§å¿èMRIã®ç°åžžæèŠãæ®ã£ãŠãã人ãããŠããããé·æçã«ã©ã®ãããªæå³ãæã€ã®ãã¯ãçŸåšãå®å šã«ã¯åãã£ãŠããŸããã
ç§ã¯ããã倧äºã ãšæããŸããã
ãå€ãã¯å埩ããããšããã®ãäºå®ã§ããã
ãã ããäœã®åé¡ããªãã£ãã
ãšãŸã§èšã£ãŠããŸãã®ãéããŸãã
éã«ãäžéšã§é·æçãªç°åžžãæ®ã£ããããšãã£ãŠã
ãmRNAã¯ã¯ãã³ãæã£ã人ã®å¿èã¯ã¿ããªå±éºã ã
ãšäžè¬åããããšãã§ããŸããã
åãã£ãŠããããšãšããŸã åãã£ãŠããªãããšãåããå¿ èŠããããŸãã
å¿çç以å€ã«ããå æé¢ä¿ã確èªãããå¯åå¿ã¯ãã£ã
ã»ãã«ããã¢ããã£ã©ãã·ãŒããAstraZenecaãJohnson & Johnsonãªã©ã®ã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒã¯ã¯ãã³ã§èµ·ããTTSãšããè¡æ çãç¹å®ã®è£œå€ã§ã®ã®ã©ã³ã»ãã¬ãŒçå矀ãªã©ã確èªãããŠããŸãã
ããã§æ°ãã€ãããã®ã¯ãããããå šéšãã³ããã¯ã¯ãã³ã®å¯äœçšããšãŸãšããŠããŸããªãããšã§ãã
PfizerãModernaãAstraZenecaãJohnson & Johnsonã§ã¯ä»çµã¿ãéããŸãããå¯åå¿ã®çš®é¡ãé »åºŠãéããŸãã
ãã¯ã¯ãã³ããšããäžèšã ãã§ã¯ãæ¬åœã¯ããªã倧ãã£ã±ãªã®ã§ãã
ã§ã¯ãã¯ã¯ãã³æ¥çš®åŸã«äº¡ããªã£ã人ã倿°ããããšãã話ã¯ïŒ
ããã¯ä»åãç§ãç¹ã«æ··ä¹±ããéšåã§ããã
ãšããã®ãã調ã¹ããšã
ãæ¥çš®åŸæ»äº¡ã2,000件以äžå ±åãããŠããã
ãšããæ°åãããã°ã
ãåœã1,000件以äžã®æ»äº¡ãææžèªå®ããŠããã
ãšããæ°åãåºãŠããããã§ãã
ããããæ°åã ããèŠããšã
ããã£ã±ãã¯ã¯ãã³ã§1,000人ã2,000人åäœã§äº¡ããªã£ãã®ã§ã¯ïŒã
ãšæã人ãããŠãäžæè°ã§ã¯ãããŸããã
ãšããã調ã¹ãŠã¿ããšããã®æ°åã¯ããããæå³ãéããŸããã
ãæ¥çš®åŸæ»äº¡å ±åãã¯ãã¯ã¯ãã³ã«ããæ»äº¡èªå®ãã§ã¯ãªã
åçåŽåçã®èª¬æã§ã¯ã2025幎4æ14æ¥æç¹ã§ãæ°åã³ããã¯ã¯ãã³æ¥çš®åŸã®æ»äº¡ãšããŠçޝèš2,283ä»¶ãå ±åãããŠããŸããïŒAstraZenecaãé€ãåºåïŒã
ãã ããããã¯ã
ãæ¥çš®åŸã«æ»äº¡ãããããå®å šæ§ã確èªããç®çã§å ±åãããã±ãŒã¹ã
ã§ãã
æ¥çš®ããç¿æ¥ã«äº€éäºæ ã§äº¡ããªã£ãå Žåã®ãããªæ¥µç«¯ãªäŸãæ³åãããšåãããããã§ããããæ¥çš®ã®åŸã«èµ·ããããšããæéçãªé¢ä¿ã ãã§ã¯ããæ¥çš®ãåå ã ã£ãããšã¯å€æã§ããŸããã
ã ããå®å šæ§ç£èŠã§ã¯ãå ±åãããçäŸã«ã€ããŠãç æŽãçºçææãã»ãã®åå ã®å¯èœæ§ãªã©ã調ã¹ãŠãããŸãã
äžæ¹ã§ãããããèªçºå ±åå¶åºŠã«ã¯å ±åãããªãã±ãŒã¹ãããåŸãŸãã
ã€ãŸãã
å ±åä»¶æ°ïŒã¯ã¯ãã³ã«ããæ»äº¡äººæ°
ã§ããªããã°ã
å ±åãããŠããªãïŒã¯ã¯ãã³ãšã®é¢ä¿ã絶察ã«ãªãã£ã
ãšãèšããŸããã
åœãèªå®ãããæ»äº¡1,078ä»¶ãã¯äœãæå³ããã®ã
ããã«ãããããã®ããäºé²æ¥çš®å¥åº·è¢«å®³ææžå¶åºŠã§ãã
2026幎9æ14æ¥æç¹ã§ã¯ãæ°åã³ããã¯ã¯ãã³ã«é¢ããå¥åº·è¢«å®³ã«ã€ããŠ9,504ä»¶ãèªå®ããããã®ãã¡æ»äº¡ã«é¢ããèªå®ã¯1,078ä»¶ãšãªã£ãŠããŸããåçåŽåçãçŸç ã»é害èªå®å¯©æ»äŒã
ãã®æ°åã ããèŠããšã
ãåœã1,078人ã«ã€ããŠãã¯ã¯ãã³ãæ»äº¡åå ã ãšèªããã
ãšæã£ãŠããŸãããã§ãã
ããããå¶åºŠã®ç®çã¯è¢«å®³ãåããå¯èœæ§ã®ããäººãææžããããšã§ãããã®ãããè£å€ãç«åŠç ç©¶ã®ããã«ãã¯ã¯ãã³ãåå ã§ããããšãç§åŠçã«å³å¯ã«èšŒæãããããšãŸã§ã¯æ±ããããŠããŸããã
ã§ãããã
ã1,078人ãã¯ã¯ãã³ã«ãã£ãŠæ»äº¡ããããšãç§åŠçã«èšŒæãããã
ãšããèªã¿æ¹ã¯æ£ãããããŸããã
ãã ãå察ã«ã
ãææžå¶åºŠã ããã¯ã¯ãã³ãšã¯äœã®é¢ä¿ããªãã
ãšåãæšãŠãã®ãéããŸãã
åœãäžå®ã®åºæºã§ææžå¯Ÿè±¡ãšããŠèªããã±ãŒã¹ã1,000ä»¶ãè¶ ããŠãããšããäºå®ãã®ãã®ã¯ããã¡ããšåãæ¢ããå¿ èŠããããšæããŸãã
ãã®ãããããçæãåºãã£ãçç±ã®äžã€ãªã®ãããããªã
ä»åãããŸã§èª¿ã¹ãŠãç§ã¯äžã€çŽåŸããããšããããŸããã
ãã¯ã¯ãã³ã§ããããã®äººã亡ããªã£ãããšãã話ãåºãã£ãèæ¯ã«ã¯ãå®å šãªäœã話ã ãã§ã¯ãªããå®éã«ååšããæ°åããããšããããšã§ãã
æ¥çš®åŸã®æ»äº¡å ±åãããã
å¥åº·è¢«å®³ææžå¶åºŠã§æ»äº¡èªå®ãããã±ãŒã¹ãããã
å®éã«å æé¢ä¿ã確èªãããé倧ãªå¯åå¿ãããã
ãããŸã§èãã°ã
ããã£ã±ãå±éºã ã£ãã®ã§ã¯ïŒã
ãšèãã人ãåºãŠããã®ã¯çè§£ã§ããŸãã
ãããããã®äžã€äžã€ã®æ°åãäœãæ°ããŠããã®ããŸã§èª¿ã¹ããšããããããã®ãŸãŸãã¯ã¯ãã³ã«ããæ»äº¡è æ°ããšããããšãã§ããŸããã
ãã®ã
ãå ã«ãªã£ãäºå®ã¯ãããã§ããããããå ã®è§£éã§è©±ã倧ããå€ããã
ãšããæ§é ã¯ããã®åŸã«åºãŠããããŸããŸãªåã«ãå ±éããŠããŸããã
ãã®ä»£è¡šçãªãã®ãã
ãmRNAã¯ã¯ãã³ã¯äººéã®éºäŒåãæžãæããã®ã§ã¯ãªããïŒã
ãšãã話ã§ãã
ç§èªèº«ããã®èšèã¯äœåºŠãç®ã«ããããšããããŸãã
ã§ã¯ãããã¯ãã£ããã©ãããåºãŠãã話ã§ãå®éã«ã¯ã©ããŸã§åãã£ãŠããã®ã§ããããã
ãmRNAã¯ã¯ãã³ã¯éºäŒåãæžãæããããšããè©±ã¯æ¬åœãªã®ã
ã³ããã¯ã¯ãã³ã«ã€ããŠèª¿ã¹ãŠãããšãããªãæ©ã段éã§åºãŠããã®ãã
ãmRNAã¯ã¯ãã³ãæã€ãšã人éã®éºäŒåãæžãæããããã
ãšãã話ã§ãã
ç§ããmRNAããéºäŒåããšèããšãäœãšãªãDNAãã®ãã®ã«æãå ãããããªã€ã¡ãŒãžãæã£ãŠããŸãããããããmRNAã¯ã¯ãã³ãšããèšèèªäœãã³ããçŠã«ãªããŸã§ã»ãšãã©èããããšããããŸããã§ããã
ããã§ããã®è©±ã«ã€ããŠã調ã¹ãŠã¿ãŸããã
mRNAãšDNAã¯ãããããåããã®ã§ã¯ãªã
ããªãç°¡åã«èšãã°ã人éã®DNAã«ã¯äœãã€ããããã®æ å ±ãä¿åãããŠããŸãã
mRNAã¯ããã®DNAã«ããæ å ±ã®äžéšãããšã«ã现èãã¿ã³ãã¯è³ªãã€ããéã«äœ¿ããäžæçãªèšèšå³ãã®ãããªãã®ã§ãã
ã³ããã®mRNAã¯ã¯ãã³ã§ã¯ããŠã€ã«ã¹ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®äžéšã现èã«ã€ããããããã®mRNAãäœå ã«å ¥ãããããå ç«ã«èŠããããä»çµã¿ã䜿ãããŸããã
ã§ã¯ããã®mRNAã人éã®DNAãã®ãã®ãæžãæããã®ã§ããããã
ä»å調ã¹ãéããå®éã«ã¯ã¯ãã³ãæ¥çš®ãã人ã®DNAã«mRNAã¯ã¯ãã³ãæç¶çã«çµã¿èŸŒãŸããéºäŒåãæžãæããããšã瀺ã蚌æ ã¯ç¢ºèªã§ããŸããã§ããã
欧å·å»è¬ååºïŒEMAïŒããmRNAã¯DNAãä¿åãããŠããçŽ°èæ žã«å ¥ã£ãŠDNAãšçŽæ¥çµåãããã®ã§ã¯ãªãã人ã®éºäŒæ å ±ãæžãæãããšãã蚌æ ã¯ãªããšèª¬æããŠããŸãã(ema.europa.eu)
ã§ããããå°ãªããšãçŸåšãŸã§ã®èšŒæ ãèŠãéãã
ãmRNAã¯ã¯ãã³ãæã€ãšã人éã®éºäŒåãæžãæããããã
ãšãã衚çŸã¯æ¯æãããŠããŸããã
ã§ã¯ããäœå ã§ããã«å šéšæ¶ããããšãã説æã¯æ£ããã£ãã®ã
ãã ãããã§ã話ã¯ããã ãã§ã¯çµãããŸããã§ããã
ä»å確èªããåçåŽåçã®2026幎7æã®æ€èšè³æã§ã¯ãæ¥çš®ç±æ¥ãšèããããmRNAãæåããäžéšã®ç ç©¶ã§æ¥çš®ããæ°é±éåŸãŸã§æ€åºãããäŸãæŽçãããŠããŸãã
ã€ãŸãã
ãDNAãæžãæããã
ããšãšã
ãæ¥çš®ããmRNAããããã«ãã£ãŠã€ããããæåãäžå®æéäœå ã§æ€åºãããã
ããšã¯ããŸã£ããå¥ã®è©±ã§ãã
æ°é±éæ€åºããããããšãã£ãŠãããã人éã®DNAã«çµã¿èŸŒãŸããããšã«ã¯ãªããŸããããŸããããã ãã§äœããã®ç æ°ãèµ·ãããŠããããšã蚌æãããããã§ããããŸããã
äžæ¹ã§ããmRNAã¯æ¥çš®åŸããã«å®å šã«ãªããªããäœå ã«ã¯äžåæ®ããªãããšèšãåãã®ããçŸåšåãã£ãŠããããšãæ£ç¢ºã«è¡šçŸããŠãããšã¯èšãã«ãããã§ãã
ãã¯ã¯ãã³ã«DNAãå ¥ã£ãŠããããšãã話ããã£ã
ããã«èª¿ã¹ããšã
ãmRNAã¯ã¯ãã³ã«ã¯DNAãæ··å ¥ããŠããã
ãšãã話ãåºãŠããŸãã
ããã«ã€ããŠEMAã®çŸåšã®èª¬æãèŠããšãmRNAã補é ãããšãã«ã¯ãã©ã¹ããDNAãé³åãšããŠäœ¿çšããããã補é å·¥çšãçµãŠããã埮éã®DNAæçãæçµè£œåã«æ®ãå¯èœæ§ããããŸãã
ã€ãŸãããDNAã¯çµ¶å¯Ÿã«äžçãå ¥ã£ãŠããªãããšãã説æãæ£ç¢ºã§ã¯ãããŸããã
ãã ããEMAã¯æ®çDNAã«ã€ããŠèš±å®¹åºæºãèšå®ããŠãããEUã§æµéãã補åã調ã¹ãç ç©¶ã§ãããã®éã¯åºæºä»¥äžã ã£ããšããŠããŸãããŸããçŸåšãŸã§ã«ãã®æ®çDNAã«ããå¥åº·è¢«å®³ãã人éã®ã²ãã ãžã®æå®³ãªçµã¿èŸŒã¿ã瀺ã蚌æ ã¯ç¢ºèªããŠããªããšèª¬æããŠããŸãã(ema.europa.eu)
ãããåãã§ãã
ã埮éã®DNAæçãååšããå¯èœæ§ããããããšãšãããã®DNAã人éã®éºäŒåãæžãæãããããšã®éã«ã¯ã倧ããªè·é¢ããããŸãã
åè ãäºå®ã ãããšãã£ãŠãåŸè ãŸã§èšŒæãããããšã«ã¯ãªããŸããã
ãäžåŠã«ãªãããšãã話ã¯ã©ãã ã£ãã®ã
mRNAã¯ã¯ãã³ã«ã€ããŠã¯ããå°æ¥åã©ããã§ããªããªãããšãã話ãããªãåºãŸããŸããã
ããã«ã€ããŠããä»å確èªããç ç©¶ã§ã¯ãã¯ã¯ãã³æ¥çš®ã«ãã£ãŠç·å¥³ã®åèçã倧ããäœäžãããšããçµæã¯ç€ºãããŠããŸãããåç±³ã§åŠåš ãåžæããçŽ2,100çµã远跡ããç ç©¶ã§ããæ¥çš®ã«ããæç¢ºãªåèçäœäžã¯ç¢ºèªãããŸããã§ããã
äžæ¹ã§ãæçµåšæãäžæçã«å°ãå€åããããšã«ã€ããŠã¯ãå®éã«ç ç©¶ã§ç¢ºèªãããŠããŸãã
ã€ãŸãã
ãæ¥çš®åŸã«æçµã®å€åãèµ·ãã人ãããã
ãšãã話ããã
ãã ããäžåŠã«ãªãã
ãšé²ãã§ããŸããšãããã«ã¯èšŒæ ã®é£èºããããŸãã
ãã®äºã€ãåããŠèããå¿ èŠããããŸãã
ãã¿ãŒãçããã¯ã¯ãã³ã§ãããå¢ããããšãã話ã¯ïŒ
ããäžã€ããèŠãããã®ãããã¯ã¯ãã³æ¥çš®åŸã«ãããæ¥å¢ããããã¿ãŒãçãèµ·ããŠããããšãã話ã§ãã
ä»åã®èª¿æ»ã§ã¯ãéåœçŽ840äžäººã察象ã«ããç ç©¶ã§ãã¯ã¯ãã³æ¥çš®ãšäžéšã®ãã蚺æãšã®çµ±èšçãªé¢é£ãå ±åãããŠããããšã確èªããŸããã
ãã ãããã®ç ç©¶ã®æ¹æ³äžã®åé¡ãæ€èšããè«è©ã§ã¯ãæ¥çš®ãã人ãšããªãã£ã人ã®åèšºã»æ€èšºè¡åã芳å¯éå§æç¹ãå€éæ¯èŒãããçºçãŸã§ã®æéãªã©ãå æé¢ä¿ã倿ããããã§éèŠãªåé¡ãææãããŠããŸãã
ãã ãããã®ç ç©¶ã¯ããããšèšºæãããäººã®æ°ãã調ã¹ããã®ã§ããããæ¥éã«é²è¡ããããšã瀺ããç ç©¶ã§ã¯ãããŸããããŸãããã¿ãŒãçããšããèšèèªäœã«ããå»åŠçã«çµ±äžããã蚺æåºæºã¯ãããŸããã
ãã®ããã2026幎æç¹ã§ã¯ããmRNAã¯ã¯ãã³ãäžè¬çã«ãããå¢ãããããããã¯ããã¿ãŒãçãšããæ°ããç æ°ãåŒãèµ·ãããããšçµè«ã¥ãããã蚌æ ã¯ç¢ºèªã§ããŸããã§ããã
ãã¡ãããããã¯ãä»åŸã©ããªé·æç圱é¿ã絶察ã«èŠã€ãããªãããšããæå³ã§ã¯ãããŸããã
éåžžã«ãŸããªå¥åº·åœ±é¿ããé·ãæéããããªããã°åãããªãåé¡ã«ã€ããŠãç£èŠãç ç©¶ãç¶ããããšã¯å¿ èŠã§ãã
調ã¹ãŠã¿ããšããå®å šãªããããšäžèšã§çã¥ããã®ãéãæ°ããã
ãããŸã§èª¿ã¹ãŠãç§ãé¢çœããšæã£ãã®ã¯ãããããåã®äžã«ã¯ãåºçºç¹ã«ãªã£ãäºå®ãç ç©¶ãååšãããã®ããããšããããšã§ããã
mRNAãæåãæ°é±éæ€åºãããç ç©¶ãããã
補é å·¥çšã§ã¯DNAãé³åã«äœ¿ãã埮éã®DNAæçãæ®ãå¯èœæ§ãããã
äžæçãªæçµåšæã®å€åã確èªãããŠããã
æ¥çš®åŸã®ãã蚺æãšã®çµ±èšçãªé¢é£ãå ±åããç ç©¶ãååšããã
ããããããããã
ãã ããDNAãæžãæããããã
ãã ããäžåŠã«ãªãã
ãã ããã¿ãŒãçãèµ·ããã
ãŸã§é²ãã«ã¯ãããããå¥ã®èšŒæ ãå¿ èŠã§ãã
ä»åã®èª¿æ»ã§ã¯ããã®éšåãè£ä»ããååãªèšŒæ ã¯ç¢ºèªã§ããŸããã§ããã
ç§ã¯ãã®éããç¥ã£ãããšã§ããªãã³ããã¯ã¯ãã³ãããã話ãããã»ã©è€éã«ãªã£ãã®ããå°ãåãã£ããããªæ°ãããŸããã
ãŸã£ããæ ¹æ ã®ãªã話ã ããåºãã£ãããã§ã¯ãããŸããã
å®éã«ååšããäºå®ãç ç©¶ã«ããŸã 蚌æãããŠããªãè§£éãä»ãå ãããããããäžã€ã®å€§ããªè©±ãšããŠåºãã£ãã±ãŒã¹ãããã
ã§ã¯ãããäžã€éåžžã«ããèãã
ãã¯ã¯ãã³æ¥çš®ãå§ãŸã£ãŠãããæ¥æ¬ã®è¶ éæ»äº¡ãå¢ããã
ãšãã話ã¯ã©ããªã®ã§ããããã
å®éã«æ»äº¡è ã¯å¢ããã®ãããããŠããããã¯ã¯ãã³ãšçµã³ã€ããããšã¯ã§ããã®ãã
次ã¯ããã®ç¹ã調ã¹ãŠã¿ãŸãã
ãã¯ã¯ãã³æ¥çš®ãå§ãŸã£ãŠããè¶ éæ»äº¡ãå¢ããããšããè©±ã¯æ¬åœãªã®ã
ã³ããã¯ã¯ãã³ã«ã€ããŠèª¿ã¹ãŠãããšãããäžã€ããåºãŠããã®ãã
ãã¯ã¯ãã³æ¥çš®ãå§ãŸã£ãŠãããæ¥æ¬ã®è¶ éæ»äº¡ãå¢ããã
ãšãã話ã§ãã
ããã¯æ°åã確èªããŠã¿ããšãå°ãªããšããæ¥æ¬ã§2022幎以éãè¶ éæ»äº¡ã倧ããå¢ãããããšèªäœã¯äºå®ã§ããã
ãã ããåé¡ã¯ããããã§ãã
è¶ éæ»äº¡ãå¢ããããšãšããããã¯ã¯ãã³ã«ãã£ãŠå¢ããããšã¯ãåãæå³ã§ã¯ãããŸããã
ãããããè¶ éæ»äº¡ããšã¯äœãªã®ã
è¶ éæ»äº¡ãšã¯ãç°¡åã«èšãã°ã
ãéå»ã®æ»äº¡æ°ãªã©ããäºæž¬ãããæ»äº¡æ°ããšãå®éã«äº¡ããªã£ã人æ°ãã®å·®
ã§ãã
äŸãã°ãæ¬æ¥ãªã100äžäººã亡ããªããšäºæž¬ãããŠãã幎ã«105äžäººã亡ããªãã°ãåçŽåãããš5äžäººã®è¶ éæ»äº¡ããã£ãããšããèãæ¹ã§ãã
ãã ãããæ¬æ¥ãªãäœäººäº¡ããªãã¯ãã ã£ãã®ããã¯å®éã«èŠ³æž¬ã§ããæ°åã§ã¯ãããŸãããéå»ã®æ»äº¡æ°ãäººå£æ§æãé«éœ¢åãå£ç¯å€åãªã©ããçµ±èšã¢ãã«ã§æšå®ããŸãã
ãã®ãããã©ã®åºæºæéãèšç®æ¹æ³ã䜿ããã«ãã£ãŠãè¶ éæ»äº¡ã®æšèšå€ã«ã¯éããåºãŸãã
ä»åã®èª¿æ»ã§åç §ãã2025幎ã®BMJ Public Healthã®ç ç©¶ã§ã¯ãæ¥æ¬ã®è¶ éæ»äº¡ã¯2020幎ã«ã¯çŽ2äž2,000人ã®ãéå°æ»äº¡ãã ã£ãäžæ¹ã2021幎ã«ã¯çŽ3äž2,000人ã2022幎ã«ã¯çŽ11äž9,000人ã2023幎ã«ã¯çŽ9äž1,000人ã®è¶ éæ»äº¡ããã£ããšæšèšãããŠããŸãã
BMJ Public Healthãæ¥æ¬ã®2020ïœ2023幎ã®è¶ éæ»äº¡ãåæããç ç©¶ã
確ãã«ã2022幎以éã«æ»äº¡æ°ã倧ããå¢ããŠããŸãã
ãããŠæ¥æ¬ã§ã¯ã¯ãã³æ¥çš®ãæ¬æ Œçã«å§ãŸã£ãã®ã¯2021幎ã§ãã
ãã®äºã€ã䞊ã¹ãã°ã
ãã¯ã¯ãã³æ¥çš®ãå§ãŸã£ãããšã«è¶ éæ»äº¡ãå¢ããŠãããã§ã¯ãã¯ã¯ãã³ãåå ãªã®ã§ã¯ãªããïŒã
ãšããçåãåºãŠããããšèªäœã¯ãç§ã«ã¯ããã»ã©äžèªç¶ã«ã¯æããŸããã
ãã ããæ¥çš®éå§åŸã«å¢ãããã ãã§ã¯åå ãšã¯èšããªã
ããã§å€§åãªã®ãããæéçã«ååŸããŠããããšããšãåå ã«ãªã£ãŠããããšããåããããšã§ãã
äŸãã°ãå€ã«ãªããšã¢ã€ã¹ã¯ãªãŒã ã®å£²äžãå¢ããç±äžçã«ãªã人ãå¢ããŸãããããããã¢ã€ã¹ã¯ãªãŒã ãé£ã¹ãããç±äžçã«ãªã£ãããšã¯èšããŸãããäž¡æ¹ã«ãæãããšããå¥ã®åå ãããããã§ãã
è¶ éæ»äº¡ã«ã€ããŠãåãã§ãã
2022幎ãã2023幎ã«ã¯ãã¯ã¯ãã³æ¥çš®ã ãã§ãªããå€§èŠæš¡ãªCOVID-19ã®æµè¡ãé«éœ¢åãææåŸã®å¥åº·åœ±é¿ãå»çæ©é¢ã®éŒè¿«ãå蚺ã®é ããªã©ãæ»äº¡æ°ã«åœ±é¿ãåŸãããŸããŸãªããšãåæã«èµ·ããŠããŸããç ç©¶ã§ããè¶ éæ»äº¡ã®å¢å ã¯äžã€ã®åå ã§ã¯èª¬æã§ãããè€æ°ã®èŠå ãæ€èšããå¿ èŠããããšãããŠããŸããBMJ Public Health
å®éãåçåŽåçã®äººå£åæ çµ±èšã§ã¯ãCOVID-19ãåæ»å ãšããæ»äº¡ã¯2021幎ã«16,766人ã2022幎ã«47,638人ã2023幎ã«38,086人ãšãããŠããŸããåçåŽåçã人å£åæ çµ±èšã«åºã¥ãã€ã³ãã«ãšã³ã¶åã³æ°åã³ããã®å¹Žéæ»äº¡è æ°ã
ããã§ã
ãè¶ éæ»äº¡11äž9,000人ïŒã³ããæ»äº¡4äž7,638äººïŒæ®ãã¯ã¯ã¯ãã³ã«ããæ»äº¡ã
ãšããèšç®ãããããšã¯ã§ããŸããã
è¶ éæ»äº¡ã¯çµ±èšã¢ãã«ã«ãããäºæ³ãšã®å·®ãã§ãããæ»äº¡èšºææžäžã®COVID-19æ»äº¡æ°ãšã¯ããããæ°ãæ¹ãéããŸãããŸããCOVID-19ææåŸã®å¿è¡ç®¡çŸæ£ãªã©ã®åœ±é¿ããå»çãåããææãé ãã圱é¿ãªã©ããåçŽãªCOVID-19æ»äº¡æ°ã«ã¯å ¥ããªãå¯èœæ§ããããŸãã
ã§ã¯ãã¯ã¯ãã³ãšã®é¢é£ã調ã¹ãç ç©¶ã¯ãªãã®ã
ãããæ°ã«ãªã£ãã®ã§èª¿ã¹ãŸããã
ã¯ã¯ãã³æ¥çš®åæ°ãšè¶ éæ»äº¡ãšã®çµ±èšçãªé¢é£ãææãããã¯ã¯ãã³ã®åœ±é¿ããã£ãšèª¿ã¹ãã¹ãã ããšäž»åŒµããç ç©¶è ãå®éã«ããŸãã
ã€ãŸãã
ãã¯ã¯ãã³ãšã®é¢ä¿ãçãç ç©¶ãªããŠååšããªãã
ãšããããã§ããããŸããã
2026幎ã«Frontiers in Public Healthã«æ²èŒãããæ¥æ¬ã®è¶ éæ»äº¡ã«ã€ããŠã®ã¬ãã¥ãŒã§ããå埩ããè¿œå æ¥çš®ãšè¶ éæ»äº¡ãšã®çµ±èšçé¢é£ãå ±åããç ç©¶ãããããšãåãäžããŠããŸãã
ãã ãããã®ã¬ãã¥ãŒèªèº«ããããããç ç©¶ããã¯ã¯ãã³ãè¶ éæ»äº¡ãåŒãèµ·ããããšããå æé¢ä¿ãçµè«ã¥ããããšã¯ã§ããªããšããŠããŸããå°åããšã®æ¥çš®çãšæ»äº¡çãæ¯ã¹ãã ãã§ã¯ãå¹Žéœ¢ãææç¶æ³ãæç ãå»çãžã®ã¢ã¯ã»ã¹ãªã©ãã»ãã®èŠå ãååã«åãé€ããªãããã§ããFrontiers in Public Healthãæ¥æ¬ã®è¶ éæ»äº¡ãšç ç©¶äžã®èª²é¡ãæ€èšãã2026幎ã¬ãã¥ãŒã
ãããããã®ã¬ãã¥ãŒãå¿ èŠã ãšããŠããã®ã¯ã
ã誰ãããã€ææãããã€äœåã¯ã¯ãã³ãæ¥çš®ãããã®åŸã©ã®ãããªç æ°ãæ»äº¡ãèµ·ããã®ãã
ãšããå人åäœã®ããŒã¿ãçµã³ä»ããŠæ¯èŒããããšã§ãã
ã ãããé¢ä¿ãªãããšãŸã§èšãåãå¿ èŠããªã
ããã¯ãç§èªèº«ããªãæ éã«èããããšããã§ãã
çŸåšã®èšŒæ ããã¯ã
ã2022幎以éã®æ¥æ¬ã®è¶ éæ»äº¡ã®äž»ãªåå ã¯ã³ããã¯ã¯ãã³ã ã£ãã
ãšçµè«ã¥ããããšã¯ã§ããŸããã
äžæ¹ã§ã
ãã¯ã¯ãã³ãæ»äº¡ã«åœ±é¿ããã±ãŒã¹ã¯äžä»¶ããªããè¶ éæ»äº¡ãšã®é¢ä¿ãä»åŸèª¿ã¹ãå¿ èŠããªãã
ãšãŸã§èšãå¿ èŠããªããšæããŸãã
åã«èŠãããã«ãã¯ã¯ãã³ã«ããé倧ãªå¯åå¿ã¯å®éã«ååšããæ»äº¡ã«é¢ããå¥åº·è¢«å®³ææžèªå®ããããŸãã
ã ããããããäœäžäººãã¯ã¯ãã³ã§äº¡ããªã£ãããšæ°åã ãããçµè«ãåºãã®ã§ããªãããé¢ä¿ãããã¯ãããªãããšæåãã調ã¹ãå¿ èŠãåŠå®ããã®ã§ããªããå人åäœã®ããŒã¿ã§æ€èšŒããŠããããšãå¿ èŠãªã®ã§ãããã
ä»åãè¶ éæ»äº¡ã«ã€ããŠèª¿ã¹ãŠããŠãããŸãåããšããã«æ»ã£ãŠããŸããã
çåãçãŸããå ã«ãªã£ãäºå®ã¯ãããããã©ããã®äºå®ã ãã§ã¯åãšããŠåºãŸã£ã倧ããªçµè«ãŸã§ã¯èšŒæã§ããªãã
ãããŠããã®æ§é ãç¹ã«ãã衚ããŠããã®ããæ¬¡ã«èª¿ã¹ã補è¬äŒç€Ÿã®ãéã®è©±ã§ããã
ãçµå±ãã¯ã¯ãã³ã§äžçªå²ãã£ãã®ã¯è£œè¬äŒç€Ÿãªã®ã§ã¯ãªããïŒã
ããã¯åãªãåãªã®ãã
å®éã®æ±ºç®è³æãèŠãŠã¿ããšãããã«ã€ããŠã¯ããªãã¯ã£ããããæ°åãåºãŠããŸããã
補è¬äŒç€Ÿãã¯ã¯ãã³ã§è«å€§ã«å²ãããšããã®ã¯ãæ¬åœã ã£ãã®ã
æ¬¡ã«æ°ã«ãªã£ãã®ãããéã®è©±ã§ãã
ã³ããã¯ã¯ãã³ã«ã€ããŠã¯ããçµå±ãäžçªå²ãã£ãã®ã¯è£œè¬äŒç€Ÿã ã£ããã補è¬äŒç€Ÿãå©çãåŸãããã«äžçäžã§ã¯ã¯ãã³ãæãããã®ã§ã¯ãªããããšãã話ãããèŠãããŸãã
ã§ã¯å®éã補è¬äŒç€Ÿã¯ã©ããããã®ãéãåŸãã®ã§ããããã
決ç®è³æã確èªããŠã¿ããšãããã«ã€ããŠã¯ããªãã¯ã£ããããŠããŸããã
ã³ããã¯ã¯ãã³ã«ãã£ãŠãäžéšã®è£œè¬äŒç€Ÿã極ããŠå€§ããªå£²äžãå©çãåŸãããšèªäœã¯äºå®ã§ãã
Pfizerã®ã¯ã¯ãã³å£²äžã¯ã幎éçŽ380åãã«
Pfizerã®å¹Žæ¬¡å ±åã«ãããšãPfizer/BioNTechã®ã³ããã¯ã¯ãã³ãComirnatyãã«ããPfizeråŽã®å£²äžã¯ã2021幎ã«çŽ367.8åãã«ã2022幎ã«ã¯çŽ378.1åãã«ã§ãããPfizer Insights
æ¥æ¬åã«åçŽæç®ããã®ã¯çºæ¿ã«ãã£ãŠå€§ããå€ãããŸããããããã«ããŠãå¹Žéæ°å åèŠæš¡ã®å£²äžã§ãã
Pfizer 2022 Annual ReportïœComirnatyã®å£²äž
ãã ããããã§ãçŽ380åãã«å²ããããšæžãã®ã¯æ£ç¢ºã§ã¯ãããŸããã
ããã¯å£²äžã§ãã£ãŠã補é è²»ãç ç©¶éçºè²»ãBioNTechãšã®å©çåé ãªã©ãå·®ãåŒããçŽå©çã§ã¯ãªãããã§ãã
ãã®ã売äžããšãå©çãã®éãããæ°åãèŠããšãã«ã¯æå€ãšéèŠã§ãã
BioNTechãšModernaã¯ãå®éã«å·šé¡ã®å©çãäžããŠãã
äžæ¹ã§ãã¯ã¯ãã³ãäºæ¥ã®äžå¿ã ã£ãBioNTechãModernaãèŠããšãå©çã«ã€ããŠãããªã倧ããªæ°åã確èªã§ããŸãã
BioNTechã¯2021幎ã«çŽ190åãŠãŒãã®å£²äžãèšäžããçŽå©çã¯çŽ103åãŠãŒãã§ããã2022幎ãçŽå©çã¯çŽ94åãŠãŒãã«éããŠããŸããBioNTechïœ2021幎床決ç®
Modernaã2022幎ã®ã¯ã¯ãã³è£œå売äžãçŽ184åãã«ãå šç€Ÿã®çŽå©çã¯çŽ84åãã«ã§ãããModernaïœ2022幎床決ç®è³æïŒSECïŒ
ã§ãããã
ã補è¬äŒç€Ÿã¯ã³ããã¯ã¯ãã³ã§è«å€§ãªãéãåŸãã
ãšãã話ããåãªãé°è¬è«ãšããŠçã¥ããããšã¯ã§ããŸããã
å°ãªããšãäžéšã®ã¡ãŒã«ãŒã«ãšã£ãŠãã³ããã¯ã¯ãã³ãéåžžã«å€§ããªããžãã¹ã«ãªã£ãããšã¯ãå瀟èªèº«ã®æ±ºç®è³æãã確èªã§ããŸãã
éçºã«ã¯å ¬çãªãéã䜿ãããŠãã
ããã«èª¿ã¹ããšãã¯ã¯ãã³éçºã倧éçç£ã«ã¯æ¿åºã«ããæ¯æŽããããŸããã
äŸãã°ãã€ãæ¿åºã¯BioNTechã«æå€§çŽ3å7,500äžãŠãŒãã®éçºå©æãè¡ããŸãããã¢ã¡ãªã«ã§ãOperation Warp SpeedãéããŠã補è¬äŒç€Ÿãžã®ç ç©¶éçºã»è£œé æ¯æŽã倧éã®äºåè³Œå ¥ãè¡ãããŠããŸãã
Pfizerã«ã€ããŠã¯å°ã泚æãå¿ èŠã§ãã
Pfizerã¯ç±³æ¿åºããä»ç€Ÿãšåã圢ã®çŽæ¥çãªåæç ç©¶éçºå©æãåããŠã¯ããŸããã§ããããç±³æ¿åºã¯ã¯ã¯ãã³æ¿èªåã®2020幎7æã«ã1åååã19å5,000äžãã«ã§è³Œå ¥ããå¥çŽãçµãã§ããŸãã
ã€ãŸãããæ¿åºãPfizerã®éçºè²»ãå šéšåºããããšããã®ãéããŸããããå®å šã«æ°éäŒæ¥ã ãããªã¹ã¯ãè² ã£ãŠéçºã»è²©å£²ããããšããã®ãšãå°ãéããŸããæ¿åºã«ãã倧éã®äºåè³Œå ¥ã«ãã£ãŠã販売ãªã¹ã¯ã倧ãã軜æžãããé¢ããããŸãã
ãããŸã§èª¿ã¹ãã°ã
ãå ¬çãªãéã䜿ããã補è¬äŒç€Ÿã¯ãã®åŸè«å€§ãªå£²äžãå©çãåŸãã
ãšãããšãããŸã§ã¯ã確èªã§ããäºå®ã§ãã
ããããæ¿åºãšã®å¥çŽå 容ã«ã¯éå ¬ééšåããã£ã
ç§ãããã«æ°ã«ãªã£ãã®ã¯ã補è¬äŒç€Ÿãšæ¿åºãšã®å¥çŽã§ãã
EUã§ã¯ã¯ã¯ãã³è³Œå ¥å¥çŽã®äžéšãå ¬éãããŸããããééçãªã¹ã¯ãè£åãå©ççžåã«é¢ããéšåãªã©ã«é»å¡ãããããŸããã
ãã®æ å ±å ¬éãããã£ãŠè£å€ã«ãªãã2024幎ã«ã¯EUäžè¬è£å€æããæ¬§å·å§å¡äŒã«ããäžéšã®éå ¬é倿ã«ã€ããŠåé¡ããã£ããšãã倿ãåºããŠããŸããEUåžæ³è£å€æèªèº«ã®è§£èª¬ã§ããå ¬éãããå¥çŽæžã«ã¯è²¡åãªã¹ã¯ãªã©ã«ã€ããŠç·šéã»éå ¬ééšåããã£ãããšã確èªã§ããŸããEUåžæ³è£å€æïœCOVID-19ã¯ã¯ãã³è³Œå ¥å¥çŽã®æ å ±å ¬éãããã2024å¹Žå€æ±ºã®è§£èª¬
ããã«ããã®å¥çŽã«ã¯å¯åå¿ãªã©ãçããå Žåã®ãªã¹ã¯åæ ã«ã€ããŠã®æ¡é ãå«ãŸããŠããŸããã
EUåžæ³è£å€æã®èª¬æã«ããã°ãæ æãé倧ãªè£œé äžã®é倱ãªã©ãé€ããäžéšã®è²¬ä»»ãå çåœåŽãè² æ ããä»çµã¿ãèšããããŠããŸããã
ããããä»çµã¿ã«ã¯ããã³ãããã¯ãšããç·æ¥äºæ ã®äžã§ãäŒæ¥ã«éåžžããçæéã§éçºã»å€§éçç£ãããããã«ãªã¹ã¯ãåæ ããããšããçç±ããããŸãã
ãã ãå ¬çè³éã䜿ããæ¿åºã倧éè³Œå ¥ããäŒæ¥åŽãå·šé¡ã®å£²äžãåŸãå¥çŽã§ãã以äžã
ãã©ããªæ¡ä»¶ã§å¥çŽãããã®ãããã£ãšå ¬éãããã¹ãã§ã¯ãªããã
ãšããçåãåºãã®ãçè§£ã§ããŸãã
æ¥æ¬ã§ãã¯ã¯ãã³ã®è³Œå ¥å䟡ã¯å ¬è¡šãããªãã£ã
æ¥æ¬ã§ãåããããªåé¡ããããŸããã
2022幎4æã®è¡è°é¢åçåŽåå§å¡äŒã§ã¯ãæ¿åºãè³Œå ¥ããã¯ã¯ãã³ã®å䟡ã«ã€ããŠè³ªåãããŠããŸãããæ¿åºåŽã¯ã補è¬äŒç€Ÿãšã®å®ç§çŸ©åå¥çŽãããããå䟡ãæããã«ã§ããªããšçåŒããŠããŸãã
è¡è°é¢ïœ2022幎4æ15æ¥ åçåŽåå§å¡äŒäŒè°é²
ãŸããã¯ã¯ãã³é¢é£äºç®ãè³Œå ¥æ¬æ°ã§åçŽã«å²ã£ãŠãã茞éè²»ãªã©ãå«ãŸããŠãããããå®éã®1åãããè³Œå ¥äŸ¡æ Œã«ã¯ãªããªããšãã説æããããŠããŸãã
ã€ãŸããæ¥æ¬åœæ°ãçšéã§è³Œå ¥ããã¯ã¯ãã³ã«ã€ããŠããæ£ç¢ºãªå¥çŽå䟡ãäžè¬ã®äººã確èªã§ããªãéšåããã£ããšããããšã§ãã
ãããäºå®ã§ãã
ãããŸã§ç¥ããšããäœãããã®ã§ã¯ïŒããšæãæ°æã¡ã¯åãã
ç§ã¯ãããŸã§èª¿ã¹ãŠããªã補è¬äŒç€Ÿãçã人ãåºãŠããã®ãã¯ã以åããçè§£ã§ããããã«ãªããŸããã
è«å€§ãªå£²äžãšå©çã
æ¿åºã«ããç ç©¶éçºæ¯æŽã倧éè³Œå ¥ã
å¥çŽã®éå ¬ééšåã
äŒæ¥åŽã®ãªã¹ã¯ãæ¿åºãäžéšè² æ ããå¥çŽã
ããããäºå®ã ãã䞊ã¹ãã°ã
ãããã¯è£œè¬äŒç€Ÿãå²ããããããã ã£ãã®ã§ã¯ãªããïŒã
ãšèãã人ãåºãŠãäžæè°ã§ã¯ãããŸããã
ãã ãããã§ãäžã€å€§ããªé£èºããããŸãã
ã補è¬äŒç€Ÿãå²ãã£ãããšãã¯ã¯ãã³ãäžèŠã ã£ããã¯å¥ã®è©±
補è¬äŒç€Ÿãå·šé¡ã®å©çãåŸãããšã¯ãã¯ã¯ãã³ã«å¹æããªãã£ãããšã®èšŒæã«ã¯ãªããŸããã
ããã¯åããŠèããå¿ èŠããããŸãã
äŸãã°ãããè¬ãéåžžã«ããå¹ãããã®çµæäžçäžã§å£²ããã°ã補è¬äŒç€Ÿã倧ããªå©çãäžããããšã¯ããåŸãŸãã
å察ã«ãäŒæ¥ã倧ããªå©çãåŸãŠãã以äžãç ç©¶çµæã®èŠãæ¹ãæ¿ç決å®ãžã®åœ±é¿ãå©ççžåã«ã€ããŠå³ããç£èŠããå¿ èŠãããããšããè°è«ãåœç¶ãããŸãã
ã ããæ¬åœã«ç¢ºèªããªããã°ãªããªãã®ã¯ã
ãå²ãã£ããã©ãããã ãã§ã¯ãªãããã®å©çã«ãã£ãŠç ç©¶ãæ¿çãå°éå®¶ã®çºèšãæªãããã蚌æ ãããã®ã
ãšãããšããã§ãã
ä»åã®èª¿æ»ã§ããåæã®Pfizerã®èšåºè©Šéšã«ã¯äŒæ¥èªèº«ãè³éæäŸããäŒæ¥é¢ä¿è ãèè ãšããŠåå ããŠããŸãããããã¯å©ççžåãèããããã§åœç¶ç¢ºèªãã¹ãæ å ±ã§ãã
ãã ãããã®ããšã ãã§è©Šéšçµæãèåœã ã£ããšã¯èšããŸããã
ç ç©¶æ¹æ³ã確èªããèŠå¶åœå±ã«ãã審æ»ããäŒæ¥ãšã¯å¥ã«è¡ããããã®åŸã®å€§èŠæš¡ç ç©¶ã§ãåãçµæãåçŸãããããèŠãå¿ èŠããããŸãã
å®éãéçåãå ¥é¢ãæžãããšããäž»èŠãªæ¹åæ§ã«ã€ããŠã¯ããã®åŸã®è€æ°ã®å®ç€ŸäŒããŒã¿ã§ã確èªãããŠããŸãã
çµå±ããã§ãã
ã補è¬äŒç€Ÿã¯å·šé¡ã®å©çãåŸããââããã¯äºå®ã
ã§ãã
ãã ããã¯ã¯ãã³ã¯å¹æããªãã£ãã
ãã ããäžçäžã®æ¿åºã補è¬äŒç€Ÿã®ããã«åœæ°ãžæ¥çš®ãããã
ãšãããšãããŸã§ã¯ãããã ãã§ã¯èšŒæã§ããªãã
ãšããçµè«ã«ãªããŸããã
ãããŸã§èª¿ã¹ãŠã¿ããšã補è¬äŒç€Ÿãå·šé¡ã®å£²äžãå©çãåŸãããšãå ¬çè³éãã¯ã¯ãã³éçºã倧éè³Œå ¥ã«äœ¿ãããããšãããã«æ¿åºãšã®å¥çŽã«éå ¬éã®éšåããã£ãããšãªã©ããæ¬åœã«ãã¹ãŠåé¡ãªãã£ãã®ã ãããïŒããšçåãæã€èæ¯ã«ãªãäºå®ã¯ã確ãã«ãã£ãããšãåãããŸããã
ããšãã°ã¢ã¡ãªã«ã§ã¯ãOperation Warp SpeedãéããŠè€æ°ã®ã¯ã¯ãã³åè£ã®éçºã»è£œé ã«100åãã«ãè¶ ããå ¬çæ¯æŽãè¡ãããŸãããç±³æ¿åºç£æ»é¢ïŒGAOïŒãããã®å 容ãšãšãã«ãç·æ¥æã ããããæ å ±å ¬éãšéææ§ãéèŠã ãšææããŠããŸããç±³æ¿åºç£æ»é¢ïŒGAOïŒãCOVID-19ã¯ã¯ãã³éçºãžã®æ¿åºæ¯æŽã
ãŸããEUã§ã¯ã¯ã¯ãã³è³Œå
¥å¥çŽã®äŸ¡æ Œã責任åæ
ãªã©ã«éå
¬ééšåããããæ
å ±å
¬éãããã£ãŠè£å€ã«ããªã£ãŠããŸããæ¥æ¬ã§ããæ¿åºã¯è£œè¬äŒç€Ÿãšã®å®ç§çŸ©åå¥çŽãçç±ã«ãã¯ã¯ãã³ã®è³Œå
¥å䟡ãåœäŒã§æããã«ããŠããŸããã
è¡è°é¢ã2022幎4æ15æ¥ åçåŽåå§å¡äŒäŒè°é²ã
ãã ãããããã®äºå®ãããããšãšããæ¿åºãå°éå®¶ãšè£œè¬äŒç€ŸãçµèšããŠãå¿ èŠã®ãªãã¯ã¯ãã³ãåœæ°ã«æãããããšããããšã¯å¥ã®è©±ã§ãã
ä»å調ã¹ãç¯å²ã§ã¯ããããŸã§ã®çµè«ãè£ä»ãã蚌æ ã¯ç¢ºèªã§ããŸããã§ããã
ãã®ããããŸã§èª¿ã¹ãŠãç§ã¯ä»åã®ããŒãã«å ±éããäžã€ã®ãã¿ãŒã³ãèŠããŠããããã«æããŸãã
åã®åºçºç¹ã«ãªã£ãäºå®ã¯ãå®éã«ååšããããšãããã
ã§ãããã®äºå®ãããããäžã§èªãããŠãã倧ããªçµè«ãŸã§ã«ã¯ãããªãè·é¢ãããã
ã§ã¯ããããŸã§èŠãŠãããå¯äœçšããæ»äº¡ããéºäŒåããè¶ éæ»äº¡ãã補è¬äŒç€Ÿããªã©ãã³ããã¯ã¯ãã³ã«ã€ããŠããèã話ãäžåºŠãŸãšããŠã¿ããšãã©ããŸã§ãäºå®ã§ãã©ãããããŸã 蚌æãããŠããªã話ãªã®ã§ããããã
次ã¯ãä»å調ã¹ã代衚çãªçåãåããäžã€ãã€æŽçããŠã¿ãŸãã
ãããŸã§èª¿ã¹ãŠãããèãè©±ãæŽçããŠã¿ã
ãããŸã§ãã³ããã¯ã¯ãã³ã«ã€ããŠç§èªèº«ãæ°ã«ãªã£ãããšãäžã€ãã€èª¿ã¹ãŠããŸããã
ãããŠæ¹ããŠæããã®ã¯ãããããªã©ã§åºãŸã£ã話ã«ã¯ããŸã£ããæ ¹æ ã確èªã§ããªããã®ãããã°ãåºçºç¹ã«ã¯å®éã®äºå®ããã£ããã®ããããšããããšã§ãã
ããã§ããããŸã§ã®å 容ãäžåºŠæŽçããŠã¿ãŸãã
| ããèã話 | ä»å調ã¹ãŠåãã£ãããš |
|---|---|
| ã¯ã¯ãã³ã¯ææãé²ããªãã£ãã®ã ããããŸã£ããæå³ããªãã£ã | åæã«ã¯ææãçºçãä»äººãžã®äŒæãæžãã广ã確èªãããŠããŸããããã ãæéãšãšãã«äœäžããOmicronã§ã¯ææäºé²å¹æãããªã匱ãŸããŸãããäžæ¹ãç¹ã«é«éœ¢è ã§ã¯å ¥é¢ã»éçåãé²ãå¹æãæ®ããŸããã |
| ã¯ã¯ãã³ã«ã¯é倧ãªå¯äœçšãªããŠãªãã£ã | ããã¯éããŸããè¥ãç·æ§ãäžå¿ãšããmRNAã¯ã¯ãã³åŸã®å¿ççã»å¿èçãã¢ããã£ã©ãã·ãŒãç¹å®ã®ãã¯ã¿ãŒã¯ã¯ãã³ã«ããTTSãªã©ãå æé¢ä¿ã確èªãããé倧ãªå¯åå¿ããããŸãã |
| æ¥çš®åŸã«2,000人以äžäº¡ããªã£ãïŒ2,000人以äžãã¯ã¯ãã³ã§æ»äº¡ãã | ãæ¥çš®åŸæ»äº¡å ±åãã¯å®å šæ§ã調ã¹ãããã«éããããå ±åã§ããã¹ãŠãã¯ã¯ãã³ã«ããæ»äº¡ãšèªå®ããããã®ã§ã¯ãããŸãããå ±åæ°ãšå æé¢ä¿ã確èªãããæ»äº¡æ°ã¯å¥ã§ãã |
| å¥åº·è¢«å®³ææžå¶åºŠã§æ»äº¡èªå®ããã人ã¯ãå šå¡ã¯ã¯ãã³ãæ»äº¡åå ãšç§åŠçã«èšŒæããã | ãããéããŸããææžå¶åºŠã¯è¢«å®³ãåããå¯èœæ§ã®ããäººãææžããå¶åºŠã§ãç«åŠçã«å³å¯ãªå æèšŒæãæ±ããä»çµã¿ãšã¯ç°ãªããŸãããã ããèªå®ãããäºå®ãã®ãã®ã軜èŠããŠããããã§ããããŸããã |
| mRNAã¯ã¯ãã³ã¯äººéã®DNAãæžãæãã | çŸåšãŸã§ã«ã人ã®ã²ãã ã«æç¶çã«çµã¿èŸŒãŸããŠDNAãæžãæããããšã瀺ã蚌æ ã¯ç¢ºèªãããŠããŸãããäžæ¹ãäžéšã®ç ç©¶ã§ã¯mRNAãæåãæ°é±éæ€åºãããäŸãããããäœå ã«äžç¬ãæ®ããªãããšãã説æãæ£ç¢ºã§ã¯ãããŸããã |
| ã¯ã¯ãã³æ¥çš®ãæ¥æ¬ã®è¶ éæ»äº¡å¢å ã®äž»å ã ã£ã | æ¥æ¬ã§2022幎以éã«è¶ éæ»äº¡ã倧ããå¢ããããšã¯äºå®ã§ããããããã¯ã¯ãã³ããã®äž»å ãšããå æé¢ä¿ã¯çŸåšãŸã§ã«åå瀺ãããŠããŸãããCOVID-19ãã®ãã®ãé«éœ¢åãææåŸã®åœ±é¿ãå»çæäŸäœå¶ãªã©è€æ°ã®èŠå ãæ€èšããå¿ èŠããããŸãã |
| 補è¬äŒç€Ÿã¯ã³ããã¯ã¯ãã³ã§è«å€§ãªãéãåŸã | ããã¯äºå®ã§ããPfizerãBioNTechãModernaãªã©ã®æ±ºç®è³æãããã¯ã¯ãã³ã«ããå·šé¡ã®å£²äžãå©çã確èªã§ããŸãã |
| ã ããæ¿åºãšè£œè¬äŒç€ŸãçµèšããŠãå¿ èŠã®ãªãã¯ã¯ãã³ãåœæ°ã«æããã | å·šé¡ã®å©çãå ¬çè³éãå¥çŽã®éå ¬ééšåãªã©ãçåãçãŸããèæ¯ãšãªãäºå®ã¯ç¢ºèªã§ããŸããããããããããããå¿ èŠã®ãªãã¯ã¯ãã³ãæå³çã«æ¥çš®ãããããšããçµè«ãŸã§ãè£ä»ãã蚌æ ã¯ãä»åã®èª¿æ»ã§ã¯ç¢ºèªã§ããŸããã§ããã |
ããããŠäžŠã¹ãŠã¿ããšãä»åäœåºŠãåºãŠããã®ã¯ãäºå®ããšããã®äºå®ããå°ãããè§£éãã¯åãã§ã¯ãªãããšããããšã§ãããå®å
šãªäœã話ã°ããã§ã¯ãªããå®éã«èµ·ããããšãäžéæã ã£ãããšã«ããŸã 蚌æãããŠããªãè§£éãéãªã£ãŠåºãã£ãã±ãŒã¹ããããŸãã
ã§ã¯ãããã»ã©ç¶æ³ãè€éãªã®ã«ããªã2021幎ã«ã¯å€§èŠæš¡æ¥çš®ãè¡ãããä»ã¯åœæã»ã©æ¥çš®ãåŒã³ãããªããªã£ãã®ã§ããããã
ãªãä»ã¯ããã®é ã»ã©ã¯ã¯ãã³ãæã€ããã«èšãããªããªã£ãã®ã
ãããŸã§èª¿ã¹ãŠããŠãæåã«ç§ãæ±ããçåã«æ»ããŸãã
2021幎é ã«ã¯ããã¬ãã§ãèªæ²»äœã§ãè·å Žã§ããããªãå€§èŠæš¡ã«ã¯ã¯ãã³æ¥çš®ãåŒã³ãããããŠããŸããããããªã®ã«ä»ã¯ãåœæã®ãããªé°å²æ°ã¯ã»ãšãã©ãããŸããã
ã§ã¯ããã¯ã
ããã£ã±ãã¯ã¯ãã³ã¯å¿ èŠãªãã£ããšåãã£ãããã
ãªã®ã§ããããã
調ã¹ãŠã¿ããšãã©ããããåçŽã§ã¯ãããŸããã§ããã
2021幎ãšä»ã§ã¯ãããããã®æ¡ä»¶ãããªãéã
äžçªå€§ããã®ã¯ã瀟äŒå šäœã®å ç«ã®ç¶æ ãå€ãã£ãããšã§ãã
2021å¹Žã®æ¥çš®éå§åœåã¯ãæ°åã³ããã«ææããããšããªããã¯ã¯ãã³ãæ¥çš®ããããšããªã人ã倧éšåã§ããã
ããã«å¯ŸããŠçŸåšã¯ãå€ãã®äººãã¯ã¯ãã³æ¥çš®ãèªç¶ææããããã¯ãã®äž¡æ¹ãçµéšããŠããŸãã
WHOã2026幎7æã®ææ°ã®ããžã·ã§ã³ããŒããŒã§ãçŸåšã®COVID-19察çãèããåæãšããŠãSARS-CoV-2ãåŒãç¶ãæµè¡ããŠããäžæ¹ã§ãäžççã«äººå£å ç«ãé«ãç¶æ ã«ãªã£ãŠããããšãæããŠããŸããWHOãCOVID-19 vaccines: Position Paper â July 2026ã
ã€ãŸãã2021幎ã®ãã»ãšãã©å ç«ãæã£ãŠããªãç¶æ ã§åããŠæ¥çš®ãããã®ãšããã§ã«ææãæ¥çš®ãçµéšãã人ããããã«ãã1åæ¥çš®ãããã®ã§ã¯ãåŸãããå©çãåãã§ã¯ãããŸããã
ãŠã€ã«ã¹èªäœãå€ãã£ã
ããäžã€å€§ããã®ãããŠã€ã«ã¹ã®å€åã§ãã
æåã®ã¯ã¯ãã³ã¯ã2020å¹Žã«æµè¡ããŠãããŠã€ã«ã¹ãåæã«éçºãããŸããããã®åŸãAlphaãDeltaãOmicronãšå€ç°æ ªãå€ããã«ã€ããŠãã¯ã¯ãã³ã«ããææäºé²å¹æãå€åããŠãããŸããã
ç¹ã«Omicron以éã¯ãæ¥çš®ããŠããŠãææããã±ãŒã¹ãçãããªããªãããææãã®ãã®ãé²ãããšããæå³ã§ã®ã¯ã¯ãã³ã®äŸ¡å€ã¯ãåæããããªãå°ãããªããŸããã
ãã®äžæ¹ã§ãå ¥é¢ãéçåãé²ã广ã«ã€ããŠã¯ãç¹ã«é«éœ¢è ãªã©éçåãªã¹ã¯ã®é«ã人ã§åŒãç¶ã確èªãããŠããŸãã
ã ããçŸåšã¯ã
ã瀟äŒå šäœã®ææãæ¢ããããã«ãã¿ããªã§æ¥çš®ããã
ãšããäœçœ®ã¥ããããã
ãéçåãããã人ããèªåã®éçåãªã¹ã¯ãäžããã
ãšããæå³åãã匷ããªã£ãŠããŸãã
æ¥æ¬ã®å¶åºŠããå®éã«å€§ããå€ãã£ãŠãã
æ¥æ¬ã§ã¯ã2024幎3ææ«ã§å šé¡å ¬è²»ã«ããç¹äŸçãªæ¥çš®ãçµäºããŸããã
2024幎床以éã¯ãåå65æ³ä»¥äžã®äººãšãäžå®ã®æ¡ä»¶ãæºãã60ïœ64æ³ã®äººã察象ã«ãç§å¬ã«å®ææ¥çš®ãè¡ãå¶åºŠãžå€ãã£ãŠããŸãã
åçåŽåçã¯çŸåšã®å®ææ¥çš®ã«ã€ããŠãç®çããå人ã®éçåäºé²ã«ããéçè ãæžããããšããšèª¬æããŠããŸãããŸããçŸåšã®å¶åºŠã«ã¯æ¥çš®ã®åªå矩åããèªæ²»äœã«ããæ¥çš®å§å¥šã®èŠå®ããããŸãããåçåŽåçãæ°åã³ããã¯ã¯ãã³Q&Aã
2021å¹Žåœæãšã¯ãããªãéããŸãã
ã ããã
ãæã¯ããã»ã©æãŠãšèšã£ãŠããã®ã«ãä»ã¯èšããªããªã£ãããšããããšã¯ãæãå¿ èŠãªãã£ãã®ã ã
ãšã¯ããã®ãŸãŸçµã³ã€ããããŸããã
åæãšãªãç¶æ³ãã®ãã®ãå€ãã£ãŠããããã§ãã
é«éœ¢è ãšè¥ã人ãåãããã«èããªããªã£ãããšã倧ãã
ä»åã®èª¿æ»ãéããŠäœåºŠãåºãŠããã®ãã幎霢ã«ãã£ãŠåŸãããå©çã倧ããéããšããç¹ã§ããã
é«éœ¢ã«ãªãã»ã©COVID-19ã«ããå ¥é¢ãæ»äº¡ã®ãªã¹ã¯ã¯é«ããªããŸãããããã人ã§ã¯ãè¿œå æ¥çš®ã«ãã£ãŠéçåãé²ãå©çãæ¯èŒç倧ãããªããŸãã
äžæ¹ã§ãå¥åº·ãªè¥ã人ã¯ããšããšã®éçåãªã¹ã¯ãäœããããåãçžå¯Ÿçãªå¹æããã£ããšããŠããå®éã«é²ããå ¥é¢ãæ»äº¡ã®çµ¶å¯Ÿæ°ã¯å°ãããªããŸãã
ããã«è¥ãç·æ§ã§ã¯ãå ã»ã©èŠãå¿ççãªã©ã®ãªã¹ã¯ãèããªããã°ãªããŸããã
ã ããçŸåšã¯ããå šå¡ã«åãããã«äœåºŠãæ¥çš®ããããããã誰ã«ãšã£ãŠè¿œå æ¥çš®ã®å©çã倧ããã®ãããèããæ¹åã«å€ãã£ãŠãããšèŠãæ¹ã宿 ã«è¿ããã§ãã
æ²»çæ³ãå¢ããããšãç¡èŠã§ããªã
2021å¹Žåœæãšæ¯ã¹ãŠãCOVID-19ã«å¯Ÿããæ²»çã®éžæè¢ãå¢ããŸããã
æµè¡åæã¯ãéçåããŠããã§ããæ²»çãããªãéãããŠããŸããããã®åŸãã¹ããã€ãæ²»çãæãŠã€ã«ã¹è¬ãªã©ã䜿ãããããã«ãªããææããåŸã®å¯Ÿå¿ãå€åããŠããŸãã
ã€ãŸãçŸåšã¯ã
ãææããªãããã«ã¯ã¯ã¯ãã³ãããªãã
ãšããç¶æ³ã§ãã
ãææãããæå¹ãªæ²»çæ³ãã»ãšãã©ãªãã
ãšããç¶æ³ã§ããããŸããã
ã¯ã¯ãã³ã ããå€ãã£ãã®ã§ã¯ãªããCOVID-19ãåãå·»ãç°å¢å šäœãå€ãã£ãã®ã§ãã
ã ããããæã¯æ£ããã£ãïŒä»ã¯ééãããšãã話ã§ããªã
ãããŸã§èª¿ã¹ããšãç§ã¯ãã®éšåãããªãæŽçã§ããŸããã
2021幎ã«é«éœ¢è ãªã©éçåãªã¹ã¯ã®é«ã人ãžååæ¥çš®ãè¡ã£ãããšã«ã¯ããã®æç¹ã§ããªãåŒ·ãæ ¹æ ããããŸããã
äžæ¹ã§ããã®åŸãè¥ãå¥åº·ãªäººãå«ããŠäœåºŠãåãããã«è¿œå æ¥çš®ããããšã«ã€ããŠã¯ãåŸãããå©çãå°ãããªããå¯äœçšãè²»çšããã§ã«æã£ãŠããå ç«ãªã©ãå«ããŠèããå¿ èŠãåºãŠããŸããã
ã€ãŸãã
ã2021幎ã«ã¯å¿ èŠæ§ãé«ãã£ããããšãšãã2026幎ã«ãå šå¡ãåãããã«æ¥çš®ããå¿ èŠããããããšã¯ããŸã£ããå¥ã®è©±ã§ãã
éã«èšãã°ãçŸåšå€§èŠæš¡æ¥çš®ãããŠããªãããšã ããçç±ã«ã
ããã£ã±ãåœæã®ã¯ã¯ãã³ã¯å šéšäžèŠã ã£ãã
ãšèããã®ããå°ãéãããã«æããŸãã
ãããŸã§èª¿ã¹ãŠããŠãããããæåã®çåã«ããªãè¿ããšãããŸã§æ»ã£ãŠããŸããã
ã§ã¯çµå±ãã³ããã¯ã¯ãã³ã¯æ¬åœã«å¿ èŠã ã£ãã®ã§ããããã
æåŸã«ãä»åã®èª¿æ»ãéããŠç§èªèº«ãã©ãèããããã«ãªã£ãã®ããããŸãšããŠã¿ãããšæããŸãã
çµå±ãã³ããã¯ã¯ãã³ã¯æ¬åœã«å¿ èŠã ã£ãã®ã
ãããŸã§ããªãã®è³æã調ã¹ãŠããŸããã
æåã¯ããã³ããã¯ã¯ãã³ã¯çµå±ãå¿ èŠã ã£ãã®ããå¿ èŠãªãã£ãã®ãããšãããããå°ãåçŽãªçããåºãã®ã§ã¯ãªãããšæã£ãŠããŸããã
ã§ããå®éã«èª¿ã¹ãŠã¿ããšãç§ã®äžã§ã®çãã¯å°ãå€ãããŸããã
ãå¿ èŠã ã£ã人ã¯ç¢ºãã«ãããã§ãããã¹ãŠã®äººããã¹ãŠã®ææããã¹ãŠã®æ¥çš®ãäžæ¬ãã«ããŠãå¿ èŠã ã£ãããå¿ èŠãªãã£ãããšã¯èšããªãã
ãšããã®ããä»å調ã¹ãçµæããç§ãåãåã£ãçãã§ãã
2021幎ã®é«éœ¢è ãžã®æ¥çš®ãšããã®åŸã®è¥ã人ãžã®è¿œå æ¥çš®ã¯åã話ã§ã¯ãªã
2021å¹Žåœæãæ°åã³ããã«å¯Ÿããå ç«ãæã€äººã¯ãŸã å°ãªããæ²»çã®éžæè¢ãçŸåšããéãããŠããŸããã
ç¹ã«é«éœ¢è ãéçåãªã¹ã¯ã®é«ã人ã§ã¯ãææããå Žåã®ãªã¹ã¯ã倧ãããåæã®èšåºè©Šéšããã®åŸã®å®ç€ŸäŒããŒã¿ãèŠãŠããã¯ã¯ãã³ã«ãã£ãŠå ¥é¢ãéçåãæžããå©çã¯å€§ããã£ããšèããããŸãã
äžæ¹ã§ãå¥åº·ãª20代ã10代ãåã©ãã§ã¯ãããšããšã®éçåãªã¹ã¯ãããªãäœããªããŸãã
ããã«è¥ãç·æ§ã§ã¯å¿ççãªã©ã®å¯åå¿ã確èªããããããé«éœ¢è ãžã®ååæ¥çš®ãšãŸã£ããåãããã«ãã¡ãªããã®æ¹ã倧ããããšäžèšã§ãŸãšããããšã¯é£ããã£ãããšããä»åã®èª¿æ»ã§åãããŸããã
ãããŠOmicron以éããã§ã«ææãæ¥çš®ã«ããå ç«ãæã€äººãå¢ããäžã§ã®3åç®ã4åç®ããã以éã®æ¥çš®ãšãªãã°ãããã«å¥ã®è©±ã§ãã
çŸåšWHOããäžççã«äººå£å ç«ãé«ãŸã£ãç¶æ³ãåæãšããŠãéçåãªã¹ã¯ã®é«ãéå£ãäžå¿ãšããæ¥çš®æ¿çã瀺ããŠããŸããWHOãCOVID-19 vaccines: Position Paper â July 2026ã
ã¯ã¯ãã³ã«å¹æããã£ãããšãšãåé¡ããªãã£ãããšãå¥ã ã£ã
ããäžã€ãä»åããªãå°è±¡ã«æ®ã£ãã®ããã®ç¹ã§ãã
ã¯ã¯ãã³ã«ææã»éçåã»æ»äº¡ãæžãã广ããã£ãããšãšãã¯ã¯ãã³ããããæ¿çã説æã«åé¡ããªãã£ãããšã¯ãå¥ã®è©±ã§ããã
è¥ãç·æ§ã®å¿ççãªã©ãåœåã¯åååãã£ãŠããªãã£ãé倧ãªå¯åå¿ãåŸããæããã«ãªããŸããã
ãææãé²ããã人ã«ãã€ããªãããšãã説æã«ã€ããŠããåæã«ã¯äžå®ã®æ ¹æ ããã£ããã®ã®ããã®åŸã¯å¹æãäœäžããç¹ã«Omicron以éãåã匷ãã§èª¬æããããšã«ã¯ç¡çããããŸããã
補è¬äŒç€Ÿãå·šé¡ã®å©çãäžããããšãäºå®ã§ãã
æ¿åºãšã®å¥çŽã«éå ¬ééšåããããæ¥æ¬ã§ãè³Œå ¥å䟡ãå ¬éãããªãã£ãããšã確èªã§ããŸãããããããéšåã«ã€ããŠããã£ãšéææ§ãå¿ èŠã ã£ãã®ã§ã¯ãªããããšçåãæã€ã®ã¯ãç§ã¯ããã»ã©äžèªç¶ãªããšã§ã¯ãªããšæããŸãã
ã ãããšãã£ãŠããå šéšãŠãœã ã£ããã«ããªããªãã£ã
ãã ããããäžçªé£ãããšããã§ãã
åé¡ãäžéæãªéšåãèŠã€ãã£ããããšãã£ãŠã
ããã£ã±ãã¯ã¯ãã³ã«ã¯å¹æããªãã£ãã
ãå¯äœçšãé ããŠããã
ã補è¬äŒç€Ÿãå²ããããã ãã«æ¥çš®ãããã
ãã¯ã¯ãã³ãæ¥æ¬ã®è¶
éæ»äº¡ãåŒãèµ·ãããã
ãmRNAã«ãã£ãŠäººéã®éºäŒåãæžãæããããã
ãšãããšãããŸã§ãèªåçã«èšŒæãããããã§ã¯ãããŸããã
ä»åããªã調ã¹ãŸãããããããã倧ããªäž»åŒµã®å€ãã«ã€ããŠã¯ã2026幎çŸåšãååãªèšŒæ ã確èªããããšã¯ã§ããŸããã§ããã
ãããä»åãç§ãäžçªè峿·±ããšæã£ãã®ã¯ãåã®äžã«ãäºå®ããšãæšæž¬ããæ··ãã£ãŠããããšã§ããã
補è¬äŒç€Ÿãå·šé¡ã®å©çãåŸããããã¯äºå®ã
è¥ãç·æ§ã§å¿ççãå¢ããããããäºå®ã
æ¥çš®åŸã®æ»äº¡å ±åãå¥åº·è¢«å®³ææžå¶åºŠã«ããæ»äº¡èªå®ãããããããäºå®ã
mRNAãæåãæ¥çš®åŸãã°ããæ€åºãããç ç©¶ãããããããäºå®ã§ãã
ã§ããããããã
ãã ãã倧鿻ãåŒãèµ·ãããã
ãã ããDNAãæžãæããã
ãã ãããã¹ãŠè£œè¬äŒç€Ÿã®ããã ã£ãã
ãšçµè«ã¥ããã«ã¯ãããã«å¥ã®èšŒæ ãå¿ èŠã§ãã
ãã®äºå®ãšçµè«ã®éã«ããè·é¢ããããããSNSã§ã¯ãšãŠãèŠãã«ãããªã£ãŠããã®ã ãšæããŸãã
ãé°è¬è«ããšç¬ã£ãŠçµããããã®ãéããšæã£ã
ä»å調ã¹ãåã®ç§ã¯ããããã話ããé°è¬è«ããšããèšèã§ãŸãšããŠããŸãã°ãããã§çµãããããªæ°ãããŠããŸããã
ã§ãå®éã«èª¿ã¹ãŠã¿ããšãããã§ã¯å°ãä¹±æŽã ãšæãããã«ãªããŸããã
å¯äœçšãå®éã«ãã£ã人ãããã
æ¥çš®åŸããé·ãäœèª¿äžè¯ã蚎ããŠãã人ãããã
æ¿åºã補è¬äŒç€Ÿã®æ å ±å ¬éã«ã€ããŠããã£ãšèª¬æãå¿ èŠã ã£ããšæããéšåãããã
ã ãããçåãæã£ã人ãã®ãã®ããããããªäººããšæ±ºãã€ããŠããŸãã°ãæ¬åœã«æ€èšŒãã¹ãåé¡ãŸã§èŠããªããªã£ãŠããŸããŸãã
äžæ¹ã§ãçåãæã€ããšãšã蚌æ ããªã段éã§çããŸã§æ±ºããŠããŸãããšãéããŸãã
çãããšã¯å€§åã ããã©ãçã£ãå ã§ã蚌æ ãèŠãã
ä»åã®èšäºãæžããªãããçµå±ãããäžçªå€§äºãªã®ã§ã¯ãªãããšæããŸããã
5幎çµã£ãä»ã ãããå°ãå·éã«èŠãããããšããã
ã³ããçŠã®çã£ãã äžã§ã¯ã誰ã5幎åŸã®ããŒã¿ãç¥ãããšã¯ã§ããŸããã§ããã
æ¿åºãå°éå®¶ã補è¬äŒç€ŸãããããŠç§ãã¡äžè¬ã®äººããåãããªãããšãããããããäžã§å€æããŠããŸããã
ã ãããããä»ã«ãªã£ãŠåœæã®å€æãæ¯ãè¿ããšãã«ã¯ã
ãåœæããã®æç¹ã§äœãåãã£ãŠããã®ãã
ãšã
ããã®åŸã«ãªã£ãŠäœãåãã£ãã®ãã
ãåããŠèããå¿ èŠããããŸãã
調ã¹ãåãããçãã¯å°ãè€éã«ãªã£ã
çµå±ãç§ã¯ä»åã®èšäºãæžããŠã
ãã³ããã¯ã¯ãã³ã¯æ£ããã£ãã®ããééã£ãŠããã®ãã
ãšããåãã«ãããããªâãÃãä»ããããšã¯ã§ããŸããã§ããã
ã§ãã調ã¹ãåããåãããªããªã£ãããã§ã¯ãããŸããã
ãããã
é«éœ¢è
ãªã©ã«ã¯å€§ããªå©çããã£ãã
è¥ã人ã§ã¯å©çãšãªã¹ã¯ã®ãã©ã³ã¹ãéã£ãã
å¯äœçšã¯å®éã«ãã£ãã
補è¬äŒç€Ÿã¯å·šé¡ã®å©çãåŸãã
説æãéææ§ã«æ€èšŒãã¹ãéšåããã£ãã
ããããããããèªãããŠããå€ãã®å€§ããªé°è¬ãŸã§ãè£ä»ãã蚌æ ã¯ç¢ºèªã§ããªãã£ãã
ãšãããšãããŸã§ã¯ãããªãæŽçããããšãã§ããŸããã
ãããŠãããããããããç§ãæåã«ç¥ãããã£ãããšãªã®ã ãšæããŸãã
ã©ã¡ããã®é£å¶ã®çããä¿¡ããã®ã§ã¯ãªãã
ãå®éã«ã¯äœãåãã£ãŠããŠãäœããŸã åãããªãã®ãã
ãäžåºŠèªåã§ç¢ºãããŠã¿ãã
5幎çµã£ãä»ã ããããããã®ãšãäžçäžã§èµ·ããŠããããšããå°ãè·é¢ã眮ããŠæ¯ãè¿ãæå³ã¯ããã®ã§ã¯ãªãã§ããããã
æåŸã«
ãã®èšäºã¯ãç¹å®ã®äººã«ã¯ã¯ãã³æ¥çš®ãå§ããããæ¥çš®ããªãããšãå§ããããããã®ã§ã¯ãããŸããã
幎霢ãåºç€çŸæ£ãæææŽãéå»ã®æ¥çš®æŽãªã©ã«ãã£ãŠå€æã¯å€ãããŸããçŸåšã®æ¥çš®ã«ã€ããŠè¿·ã£ãŠããå Žåã¯ãåçåŽåçãªã©ã®ææ°æ å ±ã確èªããå¿ èŠã«å¿ããŠå»çæ©é¢ã«çžè«ããŠãã ããã
åçåŽåçãæ°åã³ããã¯ã¯ãã³ã«ã€ããŠã



ã³ã¡ã³ã